Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM	Tissue_specific
SFTPA1	COLEC4, SFTP1, SP-A, SP-A1	ENSG00000122852	Surfactant protein A1	10	79610939-79615455	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB016793, HPA042638, HPA045752, HPA049368	Supported	NA	NA	NA	NA	Tissue enriched	Tissue enriched	1180	lung: 10513.5	adrenal gland: 8.9	Group enriched	6	RPMI-8226: 29.9;U-2197: 6.8	Lung
SFTPB	SFTP3, SP-B	ENSG00000168878	Surfactant protein B	2	85657314-85668741	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002440, HPA034820, HPA062148	Enhanced	NA	NA	NA	Endometrial cancer:1.71e-6 (unfavourable), Renal cancer:2.99e-6 (unfavourable)	Group enriched	Tissue enriched	912	lung: 5318.7	adrenal gland: 5.8	Cell line enhanced	NA	BEWO: 2.8;U-2197: 6.3	Lung
SFTPC	BRICD6, PSP-C, SFTP2, SMDP2, SP-C	ENSG00000168484	Surfactant protein C	8	22156913-22164479	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA010928	Enhanced	NA	NA	NA	NA	Tissue enriched	Tissue enriched	832	lung: 25269.5	adrenal gland: 30.3	Group enriched	9	BEWO: 9.2;NB-4: 8.0;SCLC-21H: 6.1;U-2197: 24.0	Lung
SFTA3	NANCI, SFTPH	ENSG00000229415	Surfactant associated 3	14	36473288-36513829	Predicted intracellular proteins	Evidence at protein level	NA	NA	NA	NA	NA	Lung cancer:8.29e-4 (favourable)	Group enriched	Group enriched	467	lung: 85.7;thyroid gland: 49.2	stomach: 0.1	Cell line enriched	234	SCLC-21H: 23.3	Lung
SFTPA2	COLEC5, SP-A2	ENSG00000185303	Surfactant protein A2	10	79555852-79560402	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB002439, HPA042638, HPA045752, HPA049368	Enhanced	NA	NA	NA	NA	Tissue enriched	Tissue enriched	383	lung: 15972.2	prostate: 41.7	Group enriched	18	BEWO: 7.1;NB-4: 5.1;RPMI-8226: 17.9;U-2197: 13.9	Lung
SCGB3A2	LU103, PNSP1, UGRP1	ENSG00000164265	Secretoglobin family 3A member 2	5	147870682-147882191	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enriched	Tissue enriched	188	lung: 1867.1	thyroid gland: 9.9	Cell line enhanced	NA	A-431: 76.2;EFO-21: 49.6;NTERA-2: 60.1;PC-3: 279.6	Lung
AGER	RAGE, SCARJ1	ENSG00000204305	Advanced glycosylation end-product specific receptor	6	32180968-32184324	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB011682, HPA064436	Enhanced	NA	Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable)	Expressed in all	Tissue enriched	181	lung: 889.2	thyroid gland: 4.9	Cell line enhanced	NA	HEK93: 2.5;U-266/70: 2.6	Lung
NKX2-1	BCH, NKX2A, TITF1, TTF-1, TTF1	ENSG00000136352	NK2 homeobox 1	14	36516392-36521149	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000078, CAB053633, HPA074316	Enhanced	NA	Uncertain	Golgi apparatus<br>Vesicles	NA	Group enriched	Group enriched	177	lung: 101.3;thyroid gland: 103.5	stomach: 0.5	Cell line enriched	36	SCLC-21H: 119.8	Lung
CLDN18	SFTPJ	ENSG00000066405	Claudin 18	3	137998735-138033655	Predicted membrane proteins	Evidence at protein level	CAB013010, CAB013243, HPA018446	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	85	lung: 361.8;stomach: 689.7	heart muscle: 6.1	Not detected	NA	NA	Lung
C4BPA	C4BP	ENSG00000123838	Complement component 4 binding protein alpha	1	207104262-207144972	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA000926, HPA001578	Enhanced	NA	NA	NA	Endometrial cancer:6.37e-5 (favourable), Liver cancer:2.24e-4 (favourable)	Tissue enriched	Group enriched	65	liver: 997.5;lung: 262.3	cervix, uterine: 9.6	Cell line enriched	6	Hep G2: 25.8	Lung
SFTPD	COLEC7, SFTP4, SP-D	ENSG00000133661	Surfactant protein D	10	79937740-79982614	Predicted secreted proteins	Evidence at protein level	CAB004578, HPA044582, HPA056768	Enhanced	NA	NA	NA	NA	Tissue enriched	Tissue enriched	56	lung: 782.5	bone marrow: 13.8	Cell line enhanced	NA	BEWO: 1.3;hTCEpi: 2.3;MCF7: 1.1	Lung
SCN1A	FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI	ENSG00000144285	Sodium voltage-gated channel alpha subunit 1	2	165989160-166149214	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA078664	NA	NA	Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane	NA	Tissue enriched	Group enriched	41	cerebral cortex: 10.3;fallopian tube: 2.9;lung: 2.2	adrenal gland,placenta,testis: 0.1	Cell line enhanced	NA	AF22: 1.1;ASC TERT1: 4.4;Hep G2: 1.1	Lung
ROS1	c-ros-1, MCF3, ROS	ENSG00000047936	ROS proto-oncogene 1, receptor tyrosine kinase	6	117288300-117425855	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049098, HPA072424	Uncertain	NA	Approved	Vesicles	NA	Tissue enriched	Group enriched	18	epididymis: 70.9;lung: 47.2	seminal vesicle: 3.2	Cell line enhanced	NA	HSkMC: 7.5;hTCEpi: 15.7;LHCN-M2: 12.7	Lung
AQP4	MIWC	ENSG00000171885	Aquaporin 4	18	26852038-26865818	Predicted membrane proteins, Transporters	Evidence at protein level	CAB005079, HPA014784, CAB058689	Enhanced	Supported	Supported	Plasma membrane<br>Cell Junctions	NA	Tissue enriched	Group enriched	16	cerebral cortex: 630.0;lung: 171.9	thyroid gland: 24.4	Cell line enhanced	NA	AF22: 2.4;RPTEC TERT1: 1.0	Lung
CHIT1	CHI3, CHIT	ENSG00000133063	Chitinase 1	1	203212827-203273641	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA010575	Approved	NA	NA	NA	Cervical cancer:2.02e-4 (favourable)	Tissue enhanced	Group enriched	14	bone marrow: 31.3;breast: 10.9;cervix, uterine: 13.5;lung: 53.2;lymph node: 21.0	prostate,thyroid gland: 1.8	Not detected	NA	NA	Lung
GGTLC1	dJ831C21.1, dJ831C21.2, GGTLA3, GGTLA4	ENSG00000149435	Gamma-glutamyltransferase light chain 1	20	23985050-23988779	Predicted intracellular proteins	Evidence at protein level	HPA045635, HPA047534	Uncertain	NA	NA	NA	NA	Tissue enriched	Group enriched	14	lung: 38.7;testis: 15.8	thyroid gland: 1.9	Not detected	NA	NA	Lung
NAPSA	KAP, Kdap, NAP1, NAPA	ENSG00000131400	Napsin A aspartic peptidase	19	50358477-50365830	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009591, HPA045280, HPA047236, HPA047744	Enhanced	NA	NA	NA	Renal cancer:1.21e-4 (favourable)	Tissue enriched	Tissue enriched	14	lung: 1412.2	kidney: 101.4	Cell line enriched	23	U-698: 27.1	Lung
RASGRF1	CDC25, CDC25L, GNRP, GRF1, GRF55, H-GRF55, PP13187	ENSG00000058335	Ras protein specific guanine nucleotide releasing factor 1	15	78959947-79090773	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010413, HPA041965	Approved	NA	Supported	Golgi apparatus	Endometrial cancer:6.14e-6 (favourable)	Mixed	Group enriched	14	cerebral cortex: 30.5;lung: 11.3	lymph node: 1.5	Cell line enhanced	NA	A-431: 7.3;BEWO: 7.5;Karpas-707: 7.5;RPMI-8226: 9.0;U-2 OS: 15.8	Lung
CHIA	AMCase, CHIT2, TSA1902	ENSG00000134216	Chitinase, acidic	1	111290862-111320566	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059193	Approved	NA	NA	NA	NA	Tissue enhanced	Group enriched	11	lung: 15.6;stomach: 8.2	endometrium: 1.1	Cell line enhanced	NA	ASC diff: 1.1	Lung
MS4A15	NA	ENSG00000166961	Membrane spanning 4-domains A15	11	60756953-60776732	Predicted membrane proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enriched	11	lung: 71.4	endometrium: 6.2	Cell line enhanced	NA	HEL: 6.6;MOLT-4: 2.7;U-266/70: 7.9;U-266/84: 3.3	Lung
UPK3B	FLJ32198, MGC10902, p35, UPIIIb	ENSG00000243566	Uroplakin 3B	7	76510428-76516521	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010506	Approved	NA	Approved	Nucleus<br>Vesicles<br>Cytosol	NA	Group enriched	Group enriched	11	esophagus: 12.4;lung: 29.8;urinary bladder: 11.0	tonsil: 1.6	Group enriched	8	A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4	Lung
C6orf223	MGC45491	ENSG00000181577	Chromosome 6 open reading frame 223	6	44000580-44005958	Predicted intracellular proteins	Evidence at transcript level	HPA035765, HPA046117	Uncertain	NA	Approved	Nucleoli fibrillar center	Renal cancer:9.38e-5 (unfavourable), Liver cancer:4.59e-4 (unfavourable)	Mixed	Group enriched	10	breast: 22.7;lung: 5.6	duodenum: 1.3	Cell line enhanced	NA	A-431: 21.4;RPTEC TERT1: 25.1;THP-1: 9.6	Lung
DCSTAMP	DC-STAMP, FIND, TM7SF4	ENSG00000164935	Dendrocyte expressed seven transmembrane protein	8	104339087-104356689	Predicted membrane proteins, Transporters	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enriched	Group enriched	10	epididymis: 2.4;lung: 5.6	cerebral cortex,cervix, uterine,lymph node,urinary bladder: 0.3	Not detected	NA	NA	Lung
LRRN4	C20orf75, dJ1056H1.1, NLRR4	ENSG00000125872	Leucine rich repeat neuronal 4	20	6040778-6054049	Predicted membrane proteins	Evidence at protein level	HPA075974	NA	NA	Approved	Nucleoli<br>Cytosol	NA	Group enriched	Tissue enriched	10	lung: 13.5	fallopian tube: 1.2	Cell line enriched	12	RPTEC TERT1: 53.0	Lung
SFTA2	SFTPG	ENSG00000196260	Surfactant associated 2	6	30931353-30955636	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Pancreatic cancer:1.26e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	lung: 53.8	esophagus: 5.2	Group enriched	5	CACO-2: 7.9;CAPAN-2: 4.5	Lung
SLC34A2	NAPI-3B	ENSG00000157765	Solute carrier family 34 member 2	4	25655301-25678748	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037989	Enhanced	NA	NA	NA	NA	Tissue enhanced	Tissue enriched	10	lung: 1121.1	fallopian tube: 111.8	Group enriched	76	BEWO: 31.0;EFO-21: 114.1;RPTEC TERT1: 66.5	Lung
SLC6A4	5-HTT, HTT, OCD1, SERT1	ENSG00000108576	Solute carrier family 6 member 4	17	30194319-30236002	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071354, HPA074728	NA	Supported	Supported	Golgi apparatus<br>Vesicles	NA	Tissue enhanced	Group enriched	10	duodenum: 10.4;lung: 44.2;placenta: 26.4;small intestine: 45.3	esophagus: 3.1	Cell line enhanced	NA	BEWO: 1.9;CACO-2: 3.2;Hep G2: 7.1	Lung
MCEMP1	C19orf59, MGC132456	ENSG00000183019	Mast cell expressed membrane protein 1	19	7676628-7679826	Predicted membrane proteins	Evidence at protein level	HPA014731	Enhanced	NA	NA	NA	NA	Mixed	Group enriched	9	appendix: 27.9;bone marrow: 43.9;lung: 110.4	smooth muscle: 7.0	Group enriched	5	THP-1: 36.2;U-937: 130.3	Lung
MSLN	CAK1, MPF	ENSG00000102854	Mesothelin	16	760762-768865	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002216, HPA017172	Enhanced	NA	Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable)	Tissue enhanced	Group enriched	9	fallopian tube: 445.8;lung: 105.4	epididymis: 29.1	Cell line enhanced	NA	CAPAN-2: 448.3;EFO-21: 72.6;HeLa: 104.4;hTCEpi: 80.2	Lung
SCGB1A1	CC10, CC16, CCSP, UGB	ENSG00000149021	Secretoglobin family 1A member 1	11	62405103-62423195	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025686, HPA031828	Supported	NA	NA	NA	NA	Tissue enriched	Tissue enriched	9	lung: 4742.5	fallopian tube: 521.2	Cell line enriched	70	HaCaT: 1741.2	Lung
BPIFA1	bA49G10.5, LUNX, PLUNC, SPLUNC1	ENSG00000198183	BPI fold containing family A member 1	20	33235995-33243311	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025669	Supported	NA	NA	NA	NA	Tissue enriched	Group enriched	8	cervix, uterine: 9.8;lung: 26.5	urinary bladder: 2.2	Not detected	NA	NA	Lung
CYP2F1	CYP2F	ENSG00000197446	Cytochrome P450 family 2 subfamily F member 1	19	41114432-41128366	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Group enriched	8	lung: 2.4;testis: 1.9	bone marrow,esophagus,tonsil: 0.2	Group enriched	16	HMC-1: 4.7;K-562: 4.5	Lung
RTKN2	bA531F24.1, Em:AC024597.2, FLJ39352, PLEKHK1	ENSG00000182010	Rhotekin 2	10	62183035-62268707	Predicted intracellular proteins	Evidence at protein level	HPA037946, HPA038446	Enhanced	NA	Approved	Nucleoplasm<br>Mitochondria	NA	Mixed	Tissue enriched	8	lung: 121.3	testis: 14.7	Cell line enhanced	NA	A-431: 40.4	Lung
SEC14L4	dJ130H16.5, TAP3	ENSG00000133488	SEC14 like lipid binding 4	22	30488913-30505711	Predicted intracellular proteins	Evidence at protein level	HPA069748	NA	NA	Approved	Centrosome	NA	Tissue enhanced	Group enriched	8	bone marrow: 5.0;liver: 10.3;lung: 6.9;parathyroid gland: 10.5;testis: 7.1	adrenal gland: 0.9	Cell line enhanced	NA	A549: 6.7;BEWO: 36.9;SiHa: 9.8	Lung
CES1	CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1	ENSG00000198848	Carboxylesterase 1	16	55802851-55833337	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012023, HPA046717	Enhanced	NA	Enhanced	Endoplasmic reticulum	Urothelial cancer:9.92e-4 (unfavourable)	Tissue enriched	Group enriched	7	gallbladder: 399.2;liver: 1099.9;lung: 229.9	adipose tissue: 79.7	Group enriched	5	Hep G2: 414.0;THP-1: 439.1;U-937: 102.6	Lung
LAMP3	CD208, DC-LAMP, DCLAMP, LAMP, TSC403	ENSG00000078081	Lysosomal associated membrane protein 3	3	183122213-183163839	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025133, HPA051467	Enhanced	NA	Enhanced	Vesicles	Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable)	Mixed	Tissue enriched	7	lung: 319.3	appendix: 44.9	Group enriched	8	EFO-21: 154.0;HDLM-2: 40.5;HHSteC: 50.0;hTCEpi: 40.3	Lung
LGI3	NA	ENSG00000168481	Leucine rich repeat LGI family member 3	8	22146825-22157084	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024826	NA	NA	Approved	Cytosol	NA	Tissue enhanced	Group enriched	7	cerebral cortex: 76.0;lung: 23.9;skin: 17.3;thyroid gland: 21.6	esophagus: 5.2	Cell line enhanced	NA	A549: 1.0;SCLC-21H: 1.9;SK-MEL-30: 1.3;WM-115: 1.0	Lung
MROH9	ARMC11, C1orf129, FLJ23550	ENSG00000117501	Maestro heat like repeat family member 9	1	170935471-171064765	Predicted intracellular proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Not detected	Group enriched	7	fallopian tube: 3.9;lung: 1.2;testis: 2.7	endometrium: 0.3	Not detected	NA	NA	Lung
RS1	RS, XLRS1	ENSG00000102104	Retinoschisin 1	X	18639910-18672109	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA059546	Supported	NA	NA	NA	NA	Not detected	Group enriched	7	cerebral cortex: 1.1;lung: 1.6	lymph node,spleen,thyroid gland: 0.1	Not detected	NA	NA	Lung
SLC22A31	NA	ENSG00000259803	Solute carrier family 22 member 31	16	89195761-89201664	Predicted membrane proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Group enriched	Tissue enriched	7	lung: 23.0	pancreas: 3.4	Cell line enhanced	NA	BEWO: 33.0;Hep G2: 19.4;NB-4: 9.3;RPMI-8226: 11.9	Lung
ACOXL	FLJ11042	ENSG00000153093	Acyl-CoA oxidase-like	2	110732573-111118222	Predicted intracellular proteins	Evidence at protein level	HPA035392, HPA035393	NA	NA	Supported	Nucleoli<br>Cytosol	Urothelial cancer:6.48e-4 (favourable)	Group enriched	Group enriched	6	epididymis: 9.2;lung: 14.5;parathyroid gland: 6.9;prostate: 5.2;testis: 5.2;urinary bladder: 7.6	thyroid gland: 1.3	Cell line enhanced	NA	A-431: 11.1;RPMI-8226: 15.9;RT4: 23.3;U-266/70: 14.6	Lung
AGTR2	AT2, MRX88	ENSG00000180772	Angiotensin II receptor type 2	X	116170722-116174972	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Group enriched	Group enriched	6	cervix, uterine: 6.8;endometrium: 13.9;fallopian tube: 3.8;lung: 12.6;smooth muscle: 17.6	adrenal gland: 1.9	Not detected	NA	NA	Lung
CACNA2D2	KIAA0558	ENSG00000007402	Calcium voltage-gated channel auxiliary subunit alpha2delta 2	3	50362799-50504244	FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034771, HPA071829	Enhanced	NA	Approved	Vesicles	Endometrial cancer:7.62e-5 (unfavourable), Pancreatic cancer:1.21e-4 (favourable)	Tissue enhanced	Tissue enriched	6	lung: 72.9	testis: 12.4	Cell line enriched	8	SH-SY5Y: 201.7	Lung
CEACAM6	CD66c, NCA	ENSG00000086548	Carcinoembryonic antigen related cell adhesion molecule 6	19	41750977-41772208	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB008370, HPA011041	Enhanced	NA	NA	NA	NA	Mixed	Group enriched	6	bone marrow: 110.7;colon: 180.6;esophagus: 173.5;gallbladder: 189.0;lung: 405.6;rectum: 233.8	appendix: 37.6	Cell line enriched	9	A549: 140.1	Lung
COL6A5	COL29A1, FLJ35880, VWA4	ENSG00000172752	Collagen type VI alpha 5 chain	3	130345516-130484844	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA043138	Uncertain	NA	NA	NA	NA	Not detected	Group enriched	6	lung: 3.8;skin: 7.4	duodenum,stomach: 0.9	Cell line enriched	73	HDLM-2: 14.7	Lung
FCN3	FCNH, HAKA1	ENSG00000142748	Ficolin 3	1	27369112-27374824	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025945	Approved	NA	NA	NA	NA	Mixed	Group enriched	6	liver: 144.1;lung: 266.5	placenta: 33.0	Not detected	NA	NA	Lung
FHAD1	KIAA1937	ENSG00000142621	Forkhead associated phosphopeptide binding domain 1	1	15247272-15400283	Predicted intracellular proteins	Evidence at protein level	HPA054284	Enhanced	NA	NA	NA	NA	Mixed	Group enriched	6	fallopian tube: 24.1;lung: 5.2;testis: 24.7	cervix, uterine: 3.1	Group enriched	5	HDLM-2: 27.2;HMC-1: 70.7;K-562: 16.4;U-87 MG: 42.0	Lung
GPIHBP1	GPI-HBP1, LOC338328	ENSG00000277494	Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1	8	143213193-143217170	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA066302	Enhanced	NA	NA	NA	NA	Mixed	Group enriched	6	adipose tissue: 94.2;lung: 33.0	skeletal muscle: 10.5	Cell line enhanced	NA	Karpas-707: 2.3	Lung
HIGD1B	CLST11240, CLST11240-15	ENSG00000131097	HIG1 hypoxia inducible domain family member 1B	17	44846353-44850480	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Expressed in all	Group enriched	6	lung: 55.4;placenta: 153.8	gallbladder: 18.2	Mixed	NA	NA	Lung
OLR1	CLEC8A, LOX-1, SCARE1	ENSG00000173391	Oxidized low density lipoprotein receptor 1	12	10158301-10172138	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050798	NA	NA	Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Head and neck cancer:8.24e-5 (unfavourable)	Expressed in all	Group enriched	6	appendix: 41.3;cerebral cortex: 32.7;lung: 146.3;placenta: 160.9	bone marrow: 15.8	Cell line enhanced	NA	CACO-2: 102.6;HHSteC: 104.1;SiHa: 261.9;SK-BR-3: 72.4	Lung
SCGB3A1	HIN-1, HIN1, LU105, PnSP-2, UGRP2	ENSG00000161055	Secretoglobin family 3A member 1	5	180590103-180591540	Plasma proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Group enriched	Group enriched	6	breast: 125.3;cervix, uterine: 345.8;lung: 301.1;salivary gland: 193.1	stomach: 40.9	Cell line enhanced	NA	NB-4: 1.3	Lung
SDR16C5	EPHD-2, RDH-E2, RDHE2	ENSG00000170786	Short chain dehydrogenase/reductase family 16C member 5	8	56300010-56320776	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA025224	Enhanced	NA	NA	NA	Head and neck cancer:7.88e-4 (favourable)	Mixed	Group enriched	6	breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3	cervix, uterine: 5.6	Cell line enhanced	NA	CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2	Lung
SLC46A2	Ly110, TSCOT	ENSG00000119457	Solute carrier family 46 member 2	9	112878920-112890913	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA020098	Approved	NA	NA	NA	NA	Tissue enhanced	Group enriched	6	cervix, uterine: 23.3;endometrium: 5.5;epididymis: 5.7;lung: 15.1;skin: 11.3	seminal vesicle: 2.1	Not detected	NA	NA	Lung
TBX4	NA	ENSG00000121075	T-box 4	17	61452404-61485110	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB032413, HPA044457	Uncertain	NA	Approved	Vesicles	NA	Mixed	Group enriched	6	lung: 43.6;placenta: 29.8;prostate: 14.9	urinary bladder: 4.8	Cell line enhanced	NA	BJ: 2.4;THP-1: 3.9	Lung
TBX5	HOS	ENSG00000089225	T-box 5	12	114353931-114408442	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008786, HPA064683	Uncertain	NA	Approved	Nucleoplasm	NA	Mixed	Group enriched	6	heart muscle: 40.0;lung: 18.0;placenta: 46.8	prostate: 6.2	Cell line enhanced	NA	BJ: 17.0;BJ hTERT+: 36.2;BJ hTERT+ SV40 Large T+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 12.1;HAP1: 18.0	Lung
WIF1	NA	ENSG00000156076	WNT inhibitory factor 1	12	65050626-65121566	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039104	Approved	NA	NA	NA	NA	Tissue enhanced	Tissue enriched	6	lung: 159.4	cerebral cortex: 26.4	Cell line enhanced	NA	HEK93: 1.9;NTERA-2: 2.7	Lung
ANOS1	ADMLX, KAL, KAL1, KALIG-1, WFDC19	ENSG00000011201	Anosmin 1	X	8528874-8732186	Disease related genes, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Mixed	Group enriched	5	cerebral cortex: 32.3;lung: 64.7;parathyroid gland: 48.5;thyroid gland: 15.5	testis: 7.3	Group enriched	5	NTERA-2: 36.7;U-2 OS: 18.3	Lung
COX4I2	COX4-2, COX4B, COX4L2, COXIV-2, dJ857M17.2	ENSG00000131055	Cytochrome c oxidase subunit 4I2	20	31637888-31645006	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	NA	NA	NA	NA	NA	Head and neck cancer:6.04e-5 (favourable), Renal cancer:9.78e-4 (unfavourable)	Expressed in all	Group enriched	5	lung: 42.8;placenta: 157.5	thyroid gland: 19.3	Cell line enriched	5	SH-SY5Y: 1.8	Lung
LILRB3	CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB	ENSG00000204577	Leukocyte immunoglobulin like receptor B3	19	54216278-54223506	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Mixed	Group enriched	5	adipose tissue: 5.4;appendix: 11.3;bone marrow: 9.9;lung: 9.2;spleen: 11.1;urinary bladder: 6.8	placenta: 1.7	Not detected	NA	NA	Lung
OVCH1	OVCH	ENSG00000187950	Ovochymase 1	12	29412474-29497686	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA040253	Uncertain	NA	NA	NA	NA	Not detected	Group enriched	5	lung: 6.8;testis: 4.3;thyroid gland: 1.7	spleen: 0.8	Group enriched	6	Daudi: 3.9;HEL: 1.0	Lung
SLC26A9	NA	ENSG00000174502	Solute carrier family 26 member 9	1	205913048-205943460	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051485	Enhanced	NA	Approved	Nucleus<br>Cell Junctions	Head and neck cancer:8.55e-5 (favourable)	Tissue enhanced	Group enriched	5	lung: 11.4;salivary gland: 31.5;stomach: 30.8	tonsil: 4.8	Group enriched	12	CAPAN-2: 11.8;Hep G2: 3.4	Lung
TUBB1	dJ543J19.4	ENSG00000101162	Tubulin beta 1 class VI	20	59019254-59026654	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004286, HPA043640, HPA046280	Approved	NA	NA	NA	NA	Not detected	Group enriched	5	bone marrow: 4.8;lung: 2.1;placenta: 1.5;spleen: 5.6;testis: 1.5	gallbladder: 0.5	Cell line enriched	20	HEL: 24.9	Lung
ABC7-42404400C24.1	NA	ENSG00000277758	NA	10	47750864-47763592	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA036971, HPA036972, HPA064559	Approved	NA	Approved	Golgi apparatus	NA	Not detected	Tissue enhanced	NA	cerebral cortex: 13.8;lung: 19.3	skin: 5.7	Cell line enriched	7	SK-BR-3: 45.1	Lung
ABCA3	ABC-C, ABC3, EST111653, LBM180	ENSG00000167972	ATP binding cassette subfamily A member 3	16	2275881-2340746	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007884	Enhanced	NA	Approved	Nucleoplasm<br>Cytosol	NA	Expressed in all	Tissue enhanced	NA	lung: 135.5	cerebral cortex: 51.5	Cell line enhanced	NA	SCLC-21H: 53.9;T-47d: 71.7	Lung
ACP5	HPAP, TRAP	ENSG00000102575	Acid phosphatase 5, tartrate resistant	19	11574660-11579008	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002584, HPA057655, HPA059463	Enhanced	NA	Approved	Cytosol	NA	Expressed in all	Tissue enhanced	NA	lung: 254.0	lymph node: 86.3	Cell line enhanced	NA	BEWO: 36.2;SK-MEL-30: 85.3;U-138 MG: 97.5	Lung
ADAMTS8	ADAM-TS8, FLJ41712, METH2	ENSG00000134917	ADAM metallopeptidase with thrombospondin type 1 motif 8	11	130404925-130428993	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at transcript level	HPA066349	Approved	NA	NA	NA	Endometrial cancer:1.38e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	appendix: 10.9;lung: 15.5	seminal vesicle: 5.5	Cell line enhanced	NA	HMC-1: 3.2;NTERA-2: 1.8;U-2 OS: 8.7	Lung
ADGRF5	DKFZp564O1923, GPR116, KIAA0758	ENSG00000069122	Adhesion G protein-coupled receptor F5	6	46852512-46954943	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	Renal cancer:8.84e-5 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 157.8	adipose tissue: 76.2	Group enriched	8	HUVEC TERT2: 20.7;TIME: 61.2	Lung
AGBL1	CCP4, FLJ32310	ENSG00000273540	ATP/GTP binding protein like 1	15	86079973-87029052	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	lung: 1.3;skeletal muscle: 4.4	esophagus: 1.0	Not detected	NA	NA	Lung
ALDH3B1	ALDH7	ENSG00000006534	Aldehyde dehydrogenase 3 family member B1	11	68008578-68029282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038525	Uncertain	NA	NA	NA	Colorectal cancer:1.18e-4 (unfavourable), Pancreatic cancer:6.07e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	fallopian tube: 64.4;lung: 67.7	bone marrow: 30.7	Cell line enhanced	NA	A549: 137.9;CAPAN-2: 136.9	Lung
ALOX15	15-LOX-1	ENSG00000161905	Arachidonate 15-lipoxygenase	17	4630902-4642294	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004962, CAB004963, HPA013859	Approved	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	fallopian tube: 19.6;lung: 9.8	breast: 4.7	Group enriched	7	HMC-1: 13.6;MCF7: 10.8;T-47d: 3.9	Lung
ALOX5	5-LOX	ENSG00000012779	Arachidonate 5-lipoxygenase	10	45374176-45446119	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071285	Enhanced	NA	Supported	Nucleoplasm	Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 41.3	bone marrow: 28.8	Cell line enhanced	NA	BEWO: 10.4;Daudi: 22.8;HMC-1: 20.7;RT4: 14.0;U-266/70: 11.3	Lung
ALPL	HOPS, TNSALP	ENSG00000162551	Alkaline phosphatase, liver/bone/kidney	1	21509372-21578412	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007105, HPA008765, CAB020829	Enhanced	NA	Approved	Cytosol	Melanoma:7.08e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 78.8	kidney: 47.2	Group enriched	8	HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8	Lung
C11orf16	NA	ENSG00000176029	Chromosome 11 open reading frame 16	11	8920076-8933006	Predicted intracellular proteins	Evidence at transcript level	NA	NA	NA	NA	NA	Endometrial cancer:3.32e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	fallopian tube: 20.6;lung: 4.1	testis: 2.5	Not detected	NA	NA	Lung
C16orf89	MGC45438	ENSG00000153446	Chromosome 16 open reading frame 89	16	5044122-5066110	Predicted secreted proteins	Evidence at protein level	HPA013613, HPA016934	Enhanced	NA	NA	NA	NA	Group enriched	Tissue enhanced	NA	lung: 145.4;thyroid gland: 352.5	epididymis: 94.3	Cell line enhanced	NA	ASC diff: 1.4;Hep G2: 1.7;NTERA-2: 1.5;U-2197: 2.0	Lung
C1orf116	FLJ36507, MGC2742, MGC4309, SARG	ENSG00000182795	Chromosome 1 open reading frame 116	1	207018521-207032756	Predicted intracellular proteins	Evidence at protein level	HPA011888, HPA011889	Enhanced	NA	Supported	Plasma membrane<br>Cytosol	Renal cancer:1.01e-5 (favourable)	Mixed	Tissue enhanced	NA	esophagus: 112.4;lung: 109.2;prostate: 82.0	stomach: 54.9	Group enriched	5	A-431: 50.3;CAPAN-2: 87.3;HaCaT: 108.7;HBEC3-KT: 85.0;hTCEpi: 44.4;hTERT-HME1: 26.3;RPTEC TERT1: 42.8	Lung
C2	NA	ENSG00000166278	Complement C2	6	31897785-31945672	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016775	Supported	NA	NA	NA	Renal cancer:2.64e-7 (unfavourable)	Tissue enriched	Tissue enhanced	NA	liver: 86.3;lung: 42.6	placenta: 21.9	Group enriched	5	Hep G2: 30.0;Karpas-707: 94.7	Lung
C2orf91	NA	ENSG00000205086	Chromosome 2 open reading frame 91	2	41935368-41954266	Predicted intracellular proteins	Evidence at transcript level	HPA042517	Uncertain	NA	NA	NA	NA	Tissue enriched	Tissue enhanced	NA	lung: 2.5	adrenal gland: 1.0	Group enriched	6	AN3-CA: 3.8;HDLM-2: 13.8	Lung
C5orf38	CEI, IRX2NB	ENSG00000186493	Chromosome 5 open reading frame 38	5	2752131-2755397	Predicted intracellular proteins	Evidence at protein level	HPA073667	NA	NA	Enhanced	Golgi apparatus<br>Vesicles	NA	Mixed	Tissue enhanced	NA	lung: 13.7;salivary gland: 13.0	skin: 8.5	Cell line enhanced	NA	BEWO: 79.2;hTCEpi: 32.4;SiHa: 37.3	Lung
CALCRL	CGRPR, CRLR	ENSG00000064989	Calcitonin receptor like receptor	2	187343129-187448460	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008070, HPA046515	Uncertain	NA	Supported	Plasma membrane	NA	Expressed in all	Tissue enhanced	NA	lung: 114.3	adipose tissue: 76.8	Cell line enhanced	NA	HUVEC TERT2: 145.5;RPTEC TERT1: 30.7;TIME: 20.7	Lung
CASS4	C20orf32, HEFL, HEPL	ENSG00000087589	Cas scaffolding protein family member 4	20	56412112-56460387	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034217	Approved	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	appendix: 17.7;lung: 23.9	spleen: 10.7	Cell line enhanced	NA	HEL: 15.8;HMC-1: 45.4;K-562: 19.8	Lung
CAV1	CAV	ENSG00000105974	Caveolin 1	7	116524785-116561184	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB003791, HPA049326	Enhanced	NA	Supported	Golgi apparatus	Lung cancer:7.17e-5 (unfavourable), Renal cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 859.9	adipose tissue: 640.4	Cell line enhanced	NA	LHCN-M2: 1943.1	Lung
CCDC190	C1orf110, MGC48998	ENSG00000185860	Coiled-coil domain containing 190	1	162824458-162868815	Predicted intracellular proteins	Evidence at transcript level	HPA028579, HPA028584, HPA028592	Uncertain	NA	Approved	Vesicles	NA	Mixed	Tissue enhanced	NA	esophagus: 3.7;lung: 2.8	fallopian tube: 0.8	Cell line enhanced	NA	hTEC/SVTERT24-B: 3.9;HUVEC TERT2: 4.0;LHCN-M2: 6.0;TIME: 13.6;U-2197: 8.2	Lung
CCL18	AMAC-1, CKb7, DC-CK1, DCCK1, MIP-4, PARC, SCYA18	ENSG00000275385	C-C motif chemokine ligand 18	17	36064280-36072032	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	adipose tissue: 20.9;lung: 13.0;tonsil: 10.5	lymph node: 6.2	Not detected	NA	NA	Lung
CD101	IGSF2, V7	ENSG00000134256	CD101 molecule	1	117001750-117036476	CD markers, Predicted membrane proteins	Evidence at protein level	HPA049527, HPA057763	Approved	NA	Uncertain	Mitochondria	NA	Mixed	Tissue enhanced	NA	lung: 9.6	small intestine: 6.8	Cell line enriched	8	HMC-1: 24.0	Lung
CD300C	CMRF-35A, CMRF35, CMRF35A, IGSF16, LIR	ENSG00000167850	CD300c molecule	17	74541108-74546143	CD markers, Predicted membrane proteins	Evidence at transcript level	HPA014523	Approved	NA	NA	NA	Testis cancer:8.53e-5 (unfavourable)	Mixed	Tissue enhanced	NA	lung: 12.4	appendix: 9.5	Cell line enhanced	NA	HEL: 6.4;HMC-1: 29.3;U-937: 12.8	Lung
CD300LF	CD300f, CLM1, IGSF13, IREM1, NKIR	ENSG00000186074	CD300 molecule like family member f	17	74694311-74712978	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013712	Supported	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	lung: 25.6;spleen: 28.0	appendix: 18.2	Group enriched	7	THP-1: 16.6;U-937: 37.2	Lung
CLEC14A	C14orf27	ENSG00000176435	C-type lectin domain family 14 member A	14	38254103-38256369	Predicted membrane proteins	Evidence at protein level	HPA039468, HPA048119	Uncertain	NA	Supported	Endoplasmic reticulum<br>Golgi apparatus	Head and neck cancer:4.13e-6 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 76.1	adipose tissue: 40.9	Cell line enhanced	NA	fHDF/TERT166: 60.3;HUVEC TERT2: 345.4;TIME: 121.9	Lung
CLEC6A	CLECSF10, dectin-2	ENSG00000205846	C-type lectin domain family 6 member A	12	8455926-8478330	Predicted membrane proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Tissue enriched	Tissue enhanced	NA	appendix: 1.5;lung: 1.5	lymph node: 0.8	Cell line enhanced	NA	NTERA-2: 3.3	Lung
CLIC5	DFNB102	ENSG00000112782	Chloride intracellular channel 5	6	45898451-46080395	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA074371	NA	NA	Supported	Nuclear speckles<br>Plasma membrane	NA	Tissue enhanced	Tissue enhanced	NA	lung: 116.1;skeletal muscle: 119.2	heart muscle: 76.0	Group enriched	7	CAPAN-2: 13.3;EFO-21: 10.0;HDLM-2: 5.7;REH: 13.6;U-266/70: 10.5	Lung
CNTN6	NB-3	ENSG00000134115	Contactin 6	3	1092576-1404217	Predicted membrane proteins	Evidence at protein level	HPA016645	Uncertain	NA	NA	NA	NA	Group enriched	Tissue enhanced	NA	lung: 4.6;thyroid gland: 17.4	cerebral cortex: 4.0	Group enriched	22	AF22: 2.0;SH-SY5Y: 2.4	Lung
COL6A6	NA	ENSG00000206384	Collagen type VI alpha 6 chain	3	130560334-130678155	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045239	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	lung: 11.2	breast: 2.9	Not detected	NA	NA	Lung
CRTAC1	ASPIC1, CEP-68, FLJ10320	ENSG00000095713	Cartilage acidic protein 1	10	97865000-98030828	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008175	Enhanced	NA	NA	NA	Endometrial cancer:5.01e-6 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Renal cancer:1.85e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	cerebral cortex: 51.0;fallopian tube: 63.6;lung: 76.3;seminal vesicle: 48.1	urinary bladder: 12.8	Cell line enhanced	NA	HUVEC TERT2: 6.0;SCLC-21H: 5.6;SK-MEL-30: 6.3;TIME: 8.0	Lung
CSF2	GM-CSF, GMCSF	ENSG00000164400	Colony stimulating factor 2	5	132073790-132076170	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA057404, HPA062006	NA	NA	Enhanced	Vesicles	NA	Mixed	Tissue enhanced	NA	lung: 3.0	urinary bladder: 0.9	Cell line enhanced	NA	BJ hTERT+: 74.1;hTEC/SVTERT24-B: 20.9	Lung
CTD-3214H19.16	NA	ENSG00000269711	NA	19	7678501-7682854	Predicted intracellular proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	bone marrow: 14.1;lung: 11.8	duodenum: 7.7	Cell line enhanced	NA	EFO-21: 12.1;HMC-1: 18.1;NB-4: 7.8;THP-1: 22.2;U-937: 19.1	Lung
CXCL17	Dcip1, DMC, UNQ473, VCC1	ENSG00000189377	C-X-C motif chemokine ligand 17	19	42428288-42443048	Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Lung cancer:4.92e-5 (favourable), Pancreatic cancer:4.63e-4 (unfavourable)	Mixed	Tissue enhanced	NA	lung: 193.5;stomach: 289.7	esophagus: 83.1	Cell line enhanced	NA	RT4: 1.8	Lung
CYP4B1	NA	ENSG00000142973	Cytochrome P450 family 4 subfamily B member 1	1	46757838-46819413	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004331	Approved	NA	Supported	Vesicles	Cervical cancer:5.99e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	lung: 382.2	fallopian tube: 79.0	Cell line enriched	9	RT4: 234.9	Lung
DNAH5	CILD3, Dnahc5, HL1, KTGNR, PCD	ENSG00000039139	Dynein axonemal heavy chain 5	5	13690331-13944543	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037469, HPA037470	Enhanced	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	fallopian tube: 6.2;lung: 2.6	breast: 2.0	Cell line enhanced	NA	BJ hTERT+: 1.3;PC-3: 2.5;RPTEC TERT1: 1.1	Lung
EFCC1	C3orf73, CCDC48, FLJ12057	ENSG00000114654	EF-hand and coiled-coil domain containing 1	3	129001629-129040742	Predicted intracellular proteins	Evidence at transcript level	HPA042798, HPA050888	Uncertain	NA	NA	NA	Pancreatic cancer:9.70e-4 (favourable)	Mixed	Tissue enhanced	NA	lung: 4.9	spleen: 3.6	Cell line enhanced	NA	AF22: 1.3;HL-60: 3.0	Lung
EMP2	XMP	ENSG00000213853	Epithelial membrane protein 2	16	10528422-10580698	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014711	Approved	NA	Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.85e-8 (unfavourable), Glioma:1.93e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 343.9	skin: 166.6	Cell line enhanced	NA	MCF7: 205.4;SK-BR-3: 191.4	Lung
ESYT3	CHR3SYT, FAM62C	ENSG00000158220	Extended synaptotagmin 3	3	138434586-138481686	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039200	Approved	NA	NA	NA	Lung cancer:8.30e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	lung: 8.4;skin: 7.5;thyroid gland: 8.5	endometrium: 3.7	Cell line enhanced	NA	NTERA-2: 4.1;SCLC-21H: 5.2;SiHa: 1.9	Lung
FBN3	NA	ENSG00000142449	Fibrillin 3	19	8065402-8149846	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049482	Uncertain	NA	NA	NA	Endometrial cancer:5.15e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	lung: 2.1;thyroid gland: 1.8	cerebral cortex,salivary gland: 1.1	Cell line enhanced	NA	CACO-2: 3.1;NTERA-2: 12.3;REH: 16.9	Lung
FGFR4	CD334, JTK2	ENSG00000160867	Fibroblast growth factor receptor 4	5	177086886-177098144	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005196, HPA027273, HPA027369, HPA028251	Approved	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	lung: 38.9	duodenum: 21.4	Cell line enhanced	NA	CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0	Lung
FMO2	NA	ENSG00000094963	Flavin containing monooxygenase 2	1	171185208-171211230	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA028261	Approved	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	adipose tissue: 98.3;esophagus: 102.9;lung: 158.2	breast: 55.8	Group enriched	48	ASC diff: 27.9;ASC TERT1: 12.9;HSkMC: 35.2	Lung
FOLR1	FOLR	ENSG00000110195	Folate receptor 1	11	72189558-72196323	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA077030	NA	NA	Approved	Nuclear membrane	Liver cancer:2.50e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	cervix, uterine: 166.6;fallopian tube: 275.8;lung: 267.5	kidney: 152.7	Group enriched	6	HeLa: 298.2;RPTEC TERT1: 350.8	Lung
FOXA2	HNF3B	ENSG00000125798	Forkhead box A2	20	22581005-22585455	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB001388, HPA066846	Enhanced	NA	Supported	Nucleoplasm<br>Cell Junctions	Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable)	Mixed	Tissue enhanced	NA	cervix, uterine: 21.4;lung: 20.5;stomach: 31.0	liver: 11.5	Cell line enhanced	NA	A549: 16.1;HBEC3-KT: 14.5;Hep G2: 19.5;PC-3: 24.0;SCLC-21H: 52.3	Lung
GALNT5	GalNAc-T5	ENSG00000136542	Polypeptide N-acetylgalactosaminyltransferase 5	2	157257598-157314211	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008963, HPA009035	Approved	NA	Approved	Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol	NA	Mixed	Tissue enhanced	NA	lung: 18.4;rectum: 19.7;stomach: 16.8	colon: 13.9	Cell line enhanced	NA	A-431: 60.2;BJ hTERT+: 63.9;fHDF/TERT166: 72.0;HaCaT: 69.5;LHCN-M2: 65.2	Lung
GDF10	BMP-3b	ENSG00000266524	Growth differentiation factor 10	10	47300386-47313547	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015498	Uncertain	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	lung: 19.6	testis: 9.0	Cell line enhanced	NA	AF22: 14.6;MOLT-4: 2.6;SH-SY5Y: 6.4	Lung
GGT2	GGT	ENSG00000133475	Gamma-glutamyltransferase 2	22	21207973-21227637	Predicted membrane proteins	Evidence at protein level	HPA045635, HPA047534, HPA065444	Supported	NA	Approved	Vesicles	NA	Tissue enhanced	Tissue enhanced	NA	lung: 1.3;thyroid gland: 1.5	breast,salivary gland: 0.9	Cell line enhanced	NA	HDLM-2: 1.5;HeLa: 2.0;U-2197: 8.2	Lung
GGTLC3	NA	ENSG00000274252	Gamma-glutamyltransferase light chain 3	22	18516344-18518161	Predicted intracellular proteins	Evidence at protein level	HPA045635, HPA047534	Uncertain	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	lung: 1.9;testis: 1.0	small intestine: 0.5	Cell line enhanced	NA	U-2197: 1.0	Lung
GPRC5A	PEIG-1, RAI3, RAIG1, TIG1	ENSG00000013588	G protein-coupled receptor class C group 5 member A	12	12890782-12917937	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007928, HPA046526	Enhanced	NA	Enhanced	Vesicles<br>Plasma membrane	Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable)	Mixed	Tissue enhanced	NA	lung: 302.0	thyroid gland: 91.3	Cell line enhanced	NA	CAPAN-2: 1167.5;SiHa: 520.3	Lung
GPRIN2	KIAA0514, MGC15171	ENSG00000204175	G protein regulated inducer of neurite outgrowth 2	10	46549044-46555530	Predicted intracellular proteins	Evidence at protein level	HPA038129	Approved	NA	Approved	Nucleoplasm	Endometrial cancer:8.60e-8 (unfavourable), Head and neck cancer:3.47e-4 (favourable)	Mixed	Tissue enhanced	NA	lung: 18.0;skin: 18.8	small intestine: 11.7	Group enriched	5	A-431: 12.9;A549: 38.1;SiHa: 8.3;SK-BR-3: 17.1	Lung
GRP	NA	ENSG00000134443	Gastrin releasing peptide	18	59220168-59230774	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	lung: 13.4;thyroid gland: 10.4	parathyroid gland: 3.9	Group enriched	8	BJ hTERT+: 4.2;fHDF/TERT166: 5.1	Lung
HAS3	NA	ENSG00000103044	Hyaluronan synthase 3	16	69105564-69118719	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA031554, CAB033850	Supported	NA	Approved	Microtubules	Pancreatic cancer:5.36e-4 (unfavourable)	Group enriched	Tissue enhanced	NA	lung: 29.9;urinary bladder: 36.4	stomach: 11.8	Cell line enhanced	NA	HaCaT: 46.5;PC-3: 257.9;RT4: 89.2	Lung
HHIP	FLJ20992, HIP	ENSG00000164161	Hedgehog interacting protein	4	144646021-144745271	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012616	Uncertain	NA	Approved	Nucleoplasm	NA	Mixed	Tissue enhanced	NA	lung: 24.2	cerebral cortex: 10.8	Group enriched	6	HUVEC TERT2: 269.0;RH-30: 62.9;TIME: 306.5	Lung
HLA-C	D6S204, HLA-JY3, PSORS1	ENSG00000204525	Major histocompatibility complex, class I, C	6	31268749-31272130	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	lung: 744.7	small intestine: 396.9	Cell line enhanced	NA	A-431: 660.6;EFO-21: 748.1;RPTEC TERT1: 346.0;U-266/70: 367.3;U-266/84: 281.2	Lung
HLA-DMA	D6S222E, RING6	ENSG00000204257	Major histocompatibility complex, class II, DM alpha	6	32948613-32969094	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012750, HPA017295	Enhanced	NA	Approved	Vesicles	Endometrial cancer:4.64e-5 (favourable), Lung cancer:4.59e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 65.0	fallopian tube: 41.9	Cell line enhanced	NA	U-266/70: 22.0;U-266/84: 9.5;U-698: 52.4	Lung
HLA-DQA1	CELIAC1, HLA-DQA	ENSG00000196735	Major histocompatibility complex, class II, DQ alpha 1	6	32628179-32647062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012315	Enhanced	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	lung: 504.8	lymph node: 338.6	Cell line enriched	9	HDLM-2: 1315.9	Lung
HLA-DQB2	HLA-DXB	ENSG00000232629	Major histocompatibility complex, class II, DQ beta 2	6	32756098-32763534	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Breast cancer:5.55e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 8.1;skin: 13.3	tonsil: 5.9	Not detected	NA	NA	Lung
HLA-DRA	HLA-DRA1	ENSG00000204287	Major histocompatibility complex, class II, DR alpha	6	32439842-32445046	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002798, CAB015402, HPA050162, HPA053176	Enhanced	NA	NA	NA	Colorectal cancer:5.30e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 731.8;lymph node: 894.1	tonsil: 476.7	Cell line enhanced	NA	Daudi: 254.2;HDLM-2: 588.3;REH: 234.5;U-698: 247.8;U-87 MG: 236.0	Lung
HLA-DRB1	HLA-DR1B	ENSG00000196126	Major histocompatibility complex, class II, DR beta 1	6	32578769-32589848	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB015400, CAB034021, HPA043151	Enhanced	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	lung: 868.4	lymph node: 619.6	Cell line enhanced	NA	HDLM-2: 1095.2;U-87 MG: 302.0	Lung
HLA-DRB5	NA	ENSG00000198502	Major histocompatibility complex, class II, DR beta 5	6	32517343-32530287	Predicted membrane proteins	Evidence at protein level	HPA043151	Supported	NA	NA	NA	Endometrial cancer:7.89e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 530.8	lymph node: 397.6	Group enriched	7	HDLM-2: 589.3;HMC-1: 134.7;U-698: 129.3;U-87 MG: 232.1	Lung
HMCN1	ARMD1, FBLN6, FIBL-6, FIBL6	ENSG00000143341	Hemicentin 1	1	185734551-186190949	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051677	Uncertain	NA	NA	NA	Renal cancer:3.59e-7 (unfavourable)	Tissue enriched	Tissue enhanced	NA	lung: 22.3	prostate: 12.6	Group enriched	6	fHDF/TERT166: 17.3;MCF7: 58.7;SK-MEL-30: 38.8;U-138 MG: 13.5;WM-115: 43.4	Lung
HTR3C	NA	ENSG00000178084	5-hydroxytryptamine receptor 3C	3	184053047-184060671	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	lung: 1.9	duodenum: 0.4	Not detected	NA	NA	Lung
ICAM4	CD242, LW	ENSG00000105371	Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)	19	10286967-10288522	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	bone marrow: 8.7;lung: 14.5	epididymis: 2.9	Cell line enhanced	NA	HEL: 67.4;K-562: 35.3;NB-4: 20.5	Lung
INMT	NA	ENSG00000241644	Indolethylamine N-methyltransferase	7	30697985-30757602	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061343	NA	NA	Approved	Golgi apparatus<br>Vesicles	Liver cancer:5.72e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	lung: 144.8	seminal vesicle: 66.2	Group enriched	6	CACO-2: 13.8;HHSteC: 5.7	Lung
IRX2	NA	ENSG00000170561	Iroquois homeobox 2	5	2745845-2751662	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050895, HPA054669	Approved	NA	Approved	Nucleus<br>Nucleoli	Pancreatic cancer:8.84e-4 (favourable)	Mixed	Tissue enhanced	NA	breast: 29.6;lung: 28.0	skin: 19.5	Cell line enhanced	NA	AF22: 100.0;BEWO: 58.5;hTCEpi: 47.9	Lung
IRX5	IRX-2a	ENSG00000176842	Iroquois homeobox 5	16	54930862-54934485	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047130	NA	NA	Approved	Nuclear speckles<br>Microtubules<br>Cytosol	Lung cancer:4.59e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	breast: 17.9;lung: 9.6;skin: 10.1	salivary gland: 4.6	Cell line enhanced	NA	RPTEC TERT1: 20.1;T-47d: 34.4	Lung
ITGAE	CD103, HUMINAE	ENSG00000083457	Integrin subunit alpha E	17	3714628-3801243	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026461, HPA036313	Approved	NA	NA	NA	Renal cancer:1.13e-8 (unfavourable), Endometrial cancer:1.04e-4 (favourable), Urothelial cancer:3.56e-4 (favourable), Pancreatic cancer:5.78e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 9.5	small intestine: 6.2	Cell line enriched	22	MOLT-4: 9.6	Lung
ITGB6	NA	ENSG00000115221	Integrin subunit beta 6	2	160099666-160271888	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA023626, CAB073536	Approved	NA	Approved	Nucleoplasm<br>Cell Junctions<br>Centrosome	Pancreatic cancer:5.03e-6 (unfavourable)	Mixed	Tissue enhanced	NA	lung: 66.9	urinary bladder: 30.3	Cell line enhanced	NA	CAPAN-2: 122.2;RPTEC TERT1: 206.4	Lung
KCNK17	K2p17.1, TALK-2, TALK2, TASK-4, TASK4	ENSG00000124780	Potassium two pore domain channel subfamily K member 17	6	39299001-39314553	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at transcript level	HPA043892	Uncertain	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	lung: 5.6	placenta: 5.3	Cell line enriched	9	SCLC-21H: 91.6	Lung
KCNS3	Kv9.3	ENSG00000170745	Potassium voltage-gated channel modifier subfamily S member 3	2	17877847-18361616	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014864	Approved	NA	Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.53e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 35.5	skeletal muscle: 29.6	Cell line enhanced	NA	RH-30: 66.9;RT4: 38.5	Lung
KHDC3L	C6orf221, ECAT1	ENSG00000203908	KH domain containing 3 like, subcortical maternal complex member	6	73362677-73364171	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043699	Uncertain	NA	NA	NA	NA	Tissue enriched	Tissue enhanced	NA	lung: 1.0;testis: 2.2	epididymis: 0.4	Not detected	NA	NA	Lung
KHDRBS2	MGC26664, SLM-1, SLM1	ENSG00000112232	KH RNA binding domain containing, signal transduction associated 2	6	61679960-62286227	Predicted intracellular proteins	Evidence at protein level	HPA000500, HPA029392	Supported	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	cerebral cortex: 6.6;lung: 5.6;thyroid gland: 11.0	spleen: 1.8	Cell line enhanced	NA	AF22: 7.2;NTERA-2: 1.9;THP-1: 1.0	Lung
KIAA1324L	EIG121L, FLJ31340	ENSG00000164659	KIAA1324 like	7	86876906-87059699	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044527, HPA076093	Uncertain	NA	Approved	Endoplasmic reticulum	NA	Mixed	Tissue enhanced	NA	lung: 32.2	cerebral cortex: 21.7	Cell line enhanced	NA	K-562: 44.1;SCLC-21H: 45.6	Lung
KLRG2	CLEC15B, FLJ44186	ENSG00000188883	Killer cell lectin like receptor G2	7	139452690-139483712	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018199	Uncertain	NA	NA	NA	Lung cancer:8.61e-4 (favourable)	Tissue enriched	Tissue enhanced	NA	lung: 4.4;parathyroid gland: 5.7;thyroid gland: 6.8	kidney: 2.7	Cell line enhanced	NA	BEWO: 14.0;HAP1: 15.9;SCLC-21H: 8.6;SK-BR-3: 23.3	Lung
LPCAT1	AGPAT10, AGPAT9, AYTL2, FLJ12443	ENSG00000153395	Lysophosphatidylcholine acyltransferase 1	5	1456480-1523977	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012501, HPA022268	Enhanced	NA	Supported	Endoplasmic reticulum<br>Lipid droplets	Liver cancer:1.88e-8 (unfavourable), Renal cancer:2.64e-7 (unfavourable), Pancreatic cancer:4.90e-5 (favourable), Cervical cancer:7.11e-5 (unfavourable), Endometrial cancer:3.67e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 19.0;spleen: 14.7	cerebral cortex: 4.4	Cell line enhanced	NA	BEWO: 80.0;EFO-21: 74.7;PC-3: 52.0	Lung
MARCO	SCARA2	ENSG00000019169	Macrophage receptor with collagenous structure	2	118942166-118994660	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063793	Enhanced	NA	Approved	Golgi apparatus<br>Vesicles	NA	Mixed	Tissue enhanced	NA	appendix: 123.2;lung: 288.2	adipose tissue: 78.0	Cell line enhanced	NA	HaCaT: 1.5;THP-1: 1.7;U-2 OS: 2.7;U-266/70: 1.1	Lung
MATN3	EDM5, HOA	ENSG00000132031	Matrilin 3	2	19992111-20012694	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA051250	NA	NA	Approved	Endoplasmic reticulum<br>Golgi apparatus	Stomach cancer:4.74e-5 (unfavourable), Liver cancer:8.62e-5 (unfavourable), Cervical cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 20.2;placenta: 16.5	seminal vesicle: 6.2	Cell line enriched	5	Hep G2: 98.9	Lung
MMP13	CLG3	ENSG00000137745	Matrix metallopeptidase 13	11	102942995-102955734	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	lung: 1.5;urinary bladder: 1.3	appendix: 0.3	Cell line enhanced	NA	HaCaT: 15.8;PC-3: 6.2	Lung
MRC1	bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1	ENSG00000260314	Mannose receptor C-type 1	10	17809344-17911170	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA004114, HPA045134, CAB068203	Enhanced	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	lung: 179.9	placenta: 77.6	Group enriched	22	MOLT-4: 15.4;TIME: 14.0	Lung
MS4A2	APY, FCER1B, IGER, MS4A1	ENSG00000149534	Membrane spanning 4-domains A2	11	60088261-60098466	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA059967	Enhanced	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	lung: 24.8	gallbladder: 18.4	Cell line enhanced	NA	HEL: 2.4;THP-1: 1.0	Lung
MSR1	CD204, SCARA1	ENSG00000038945	Macrophage scavenger receptor 1	8	16107878-16567490	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000272, CAB032491	Enhanced	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	lung: 187.7	gallbladder: 50.2	Group enriched	6	BJ hTERT+: 86.3;REH: 37.8	Lung
MUC1	ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM	ENSG00000185499	Mucin 1, cell surface associated	1	155185824-155192916	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000036, CAB001986, HPA004179, HPA007235, HPA008855	Enhanced	NA	NA	NA	Pancreatic cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 448.0;stomach: 654.1	cervix, uterine: 288.9	Group enriched	7	CAPAN-2: 1005.2;RPTEC TERT1: 654.7;T-47d: 360.0	Lung
NCKAP5	ERIH1, ERIH2, NAP5	ENSG00000176771	NCK associated protein 5	2	132671799-133568463	Predicted intracellular proteins	Evidence at protein level	HPA034639, HPA044859	Uncertain	NA	Approved	Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol	NA	Mixed	Tissue enhanced	NA	lung: 17.3	cerebral cortex,kidney: 4.4	Cell line enriched	7	AF22: 45.7	Lung
NDNF	C4orf31, FLJ23191	ENSG00000173376	Neuron derived neurotrophic factor	4	121035613-121073021	Predicted secreted proteins	Evidence at protein level	HPA048881	NA	NA	Supported	Vesicles	Renal cancer:3.26e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	lung: 159.9;placenta: 86.6	ovary: 52.7	Cell line enhanced	NA	fHDF/TERT166: 37.8;U-266/70: 16.0;U-266/84: 60.4	Lung
NINJ2	NA	ENSG00000171840	Ninjurin 2	12	564296-663779	Predicted membrane proteins	Evidence at protein level	HPA058980	NA	NA	Approved	Endoplasmic reticulum	Head and neck cancer:5.31e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 55.6	bone marrow: 23.9	Cell line enhanced	NA	HEL: 137.2;MOLT-4: 210.8	Lung
NKD2	Naked2	ENSG00000145506	Naked cuticle homolog 2	5	1008829-1038943	Predicted intracellular proteins	Evidence at protein level	HPA049463	Uncertain	NA	NA	NA	Renal cancer:2.66e-5 (unfavourable), Melanoma:9.97e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 5.5;skin: 3.8	spleen: 2.9	Cell line enhanced	NA	BEWO: 17.2;NB-4: 11.0;RPMI-8226: 29.0	Lung
NOTCH4	INT3	ENSG00000204301	Notch 4	6	32194843-32224067	Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	Renal cancer:3.84e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 12.1	thyroid gland: 4.2	Not detected	NA	NA	Lung
NPNT	EGFL6L, POEM	ENSG00000168743	Nephronectin	4	105894775-106004027	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003711, HPA050203	Supported	NA	Approved	Nucleus<br>Cell Junctions<br>Cytosol	Renal cancer:8.28e-8 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 168.4;thyroid gland: 276.0	prostate: 136.5	Cell line enhanced	NA	BEWO: 27.8;HeLa: 22.2;RPTEC TERT1: 28.6;T-47d: 48.1	Lung
OSCAR	NA	ENSG00000170909	Osteoclast associated, immunoglobulin-like receptor	19	54094668-54102692	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Renal cancer:2.71e-5 (unfavourable)	Expressed in all	Tissue enhanced	NA	bone marrow: 9.0;lung: 14.1	appendix: 3.3	Cell line enhanced	NA	EFO-21: 13.1;HHSteC: 7.9;U-937: 14.0	Lung
PCDHA12	PCDH-ALPHA12	ENSG00000251664	Protocadherin alpha 12	5	140875302-141012344	Predicted membrane proteins	Evidence at transcript level	HPA035812	Approved	NA	Approved	Cytosol	NA	Not detected	Tissue enhanced	NA	lung: 2.7	cerebral cortex: 1.8	Cell line enhanced	NA	A549: 6.8;hTCEpi: 3.3;PC-3: 5.3;RT4: 4.6;SH-SY5Y: 3.3	Lung
PCSK9	FH3, HCHOLA3, NARC-1	ENSG00000169174	Proprotein convertase subtilisin/kexin type 9	1	55039548-55064852	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Urothelial cancer:2.40e-4 (unfavourable)	Mixed	Tissue enhanced	NA	liver: 6.1;lung: 11.1	colon: 3.4	Cell line enhanced	NA	A-431: 72.0;HaCaT: 94.8;HeLa: 62.7;RPTEC TERT1: 39.4	Lung
PEBP4	CORK1, hPEBP4, MGC22776	ENSG00000134020	Phosphatidylethanolamine binding protein 4	8	22713251-23000000	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA025064	Uncertain	NA	NA	NA	NA	Group enriched	Tissue enhanced	NA	epididymis: 470.5;lung: 173.6;skeletal muscle: 233.0	thyroid gland: 96.3	Cell line enriched	7	U-266/70: 3.0	Lung
PLA2G3	GIII-SPLA2	ENSG00000100078	Phospholipase A2 group III	22	31134809-31140607	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA021016	Uncertain	NA	NA	NA	Head and neck cancer:4.47e-4 (favourable)	Mixed	Tissue enhanced	NA	esophagus: 4.4;lung: 3.6;skin: 10.2	parathyroid gland: 1.5	Group enriched	6	AF22: 14.3;AN3-CA: 13.6;NTERA-2: 7.5;SCLC-21H: 13.2	Lung
PRX	KIAA1620	ENSG00000105227	Periaxin	19	40393768-40413366	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001868	Enhanced	NA	Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	NA	Expressed in all	Tissue enhanced	NA	lung: 28.8	parathyroid gland: 9.4	Mixed	NA	NA	Lung
PTGIR	IP	ENSG00000160013	Prostaglandin I2 (prostacyclin) receptor (IP)	19	46620468-46625118	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable)	Mixed	Tissue enhanced	NA	lung: 13.9	appendix: 8.2	Cell line enhanced	NA	BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3	Lung
RAMP3	NA	ENSG00000122679	Receptor activity modifying protein 3	7	45157791-45186302	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	Liver cancer:2.50e-6 (favourable), Cervical cancer:2.89e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 120.2	thyroid gland: 66.3	Cell line enhanced	NA	Karpas-707: 1.8	Lung
RP1	DCDC4A, ORP1	ENSG00000104237	RP1, axonemal microtubule associated	8	54554361-54871720	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042257	Supported	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	fallopian tube: 16.3;lung: 5.4	testis: 2.4	Cell line enhanced	NA	HDLM-2: 4.8;RPTEC TERT1: 7.7;U-2197: 2.2	Lung
RP11-40A7.2	NA	ENSG00000283526	NA	9	131545514-131558620	Predicted membrane proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	NA	Tissue enhanced	NA	fallopian tube: 10.2;lung: 6.2	prostate: 4.0	Group enriched	11	A549: 13.2;BEWO: 9.2;MCF7: 3.0;T-47d: 6.8	Lung
RSPO4	C20orf182, dJ824F16.3	ENSG00000101282	R-spondin 4	20	958452-1002264	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA048887	Uncertain	NA	NA	NA	Endometrial cancer:2.98e-6 (unfavourable)	Mixed	Tissue enhanced	NA	lung: 6.8	testis: 2.4	Cell line enhanced	NA	BEWO: 3.0;NTERA-2: 6.4;SK-BR-3: 3.3;U-2 OS: 7.7	Lung
S100A3	S100E	ENSG00000188015	S100 calcium binding protein A3	1	153547329-153549372	Predicted intracellular proteins	Evidence at protein level	HPA042674, HPA056140	Approved	NA	Enhanced	Nucleoli<br>Cytosol	Renal cancer:1.61e-6 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 19.9;skin: 17.3	esophagus: 7.5	Cell line enhanced	NA	A549: 71.3;U-2197: 41.8	Lung
SCTR	NA	ENSG00000080293	Secretin receptor	2	119439843-119525301	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA007269	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	duodenum: 26.7;lung: 12.7;pancreas: 14.4	stomach: 4.1	Cell line enhanced	NA	Karpas-707: 2.2	Lung
SEC14L3	TAP2	ENSG00000100012	SEC14 like lipid binding 3	22	30447959-30472049	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059450	Uncertain	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	bone marrow: 2.3;lung: 1.5;thyroid gland: 2.8	liver: 1.4	Not detected	NA	NA	Lung
SHROOM4	KIAA1202	ENSG00000158352	Shroom family member 4	X	50591647-50814302	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA010565	Uncertain	NA	NA	NA	Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:8.37e-4 (unfavourable)	Mixed	Tissue enhanced	NA	lung: 19.2	placenta: 13.1	Cell line enhanced	NA	EFO-21: 6.5;HUVEC TERT2: 22.2;TIME: 8.3	Lung
SLC11A1	LSH, NRAMP, NRAMP1	ENSG00000018280	Solute carrier family 11 member 1	2	218382029-218396894	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029590	Uncertain	NA	NA	NA	Renal cancer:2.58e-8 (unfavourable)	Mixed	Tissue enhanced	NA	appendix: 9.1;lung: 13.0	spleen: 4.6	Not detected	NA	NA	Lung
SLC39A8	BIGM103	ENSG00000138821	Solute carrier family 39 member 8	4	102251041-102431258	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038832, HPA038833	Approved	NA	NA	NA	Renal cancer:6.34e-6 (favourable), Colorectal cancer:1.34e-4 (favourable), Breast cancer:6.69e-4 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 257.0	cervix, uterine: 129.4	Cell line enhanced	NA	BJ hTERT+: 128.9;Karpas-707: 123.0	Lung
SLC6A14	NA	ENSG00000268104	Solute carrier family 6 member 14	X	116436622-116461458	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA003193	Uncertain	NA	Approved	Vesicles	Pancreatic cancer:9.74e-4 (unfavourable)	Mixed	Tissue enhanced	NA	cervix, uterine: 11.0;lung: 23.9	breast: 9.1	Cell line enhanced	NA	HeLa: 1.0;Hep G2: 2.3	Lung
SLC6A5	GLYT2, NET1	ENSG00000165970	Solute carrier family 6 member 5	11	20599400-20659285	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	NA	NA	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	lung: 1.4	testis: 0.6	Not detected	NA	NA	Lung
SMAD6	HsT17432, MADH6, MADH7	ENSG00000137834	SMAD family member 6	15	66702228-66782848	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061917	NA	NA	Supported	Nucleus<br>Nuclear bodies<br>Golgi apparatus	Urothelial cancer:5.45e-5 (favourable)	Expressed in all	Tissue enhanced	NA	lung: 16.8	placenta: 10.7	Cell line enhanced	NA	EFO-21: 28.0	Lung
SOSTDC1	DAND7, DKFZp564D206, USAG1	ENSG00000171243	Sclerostin domain containing 1	7	16461481-16530580	Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Renal cancer:3.22e-5 (favourable), Ovarian cancer:8.69e-4 (favourable), Urothelial cancer:8.72e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	lung: 57.1;stomach: 53.4	kidney: 23.0	Cell line enhanced	NA	AF22: 8.0;EFO-21: 11.2;NTERA-2: 4.7;RPTEC TERT1: 16.9	Lung
SPN	CD43, GPL115, LSN	ENSG00000197471	Sialophorin	16	29662979-29670876	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002666, HPA055244	Enhanced	NA	Uncertain	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable)	Expressed in all	Tissue enhanced	NA	bone marrow: 38.6;lung: 33.3	lymph node: 25.4	Cell line enhanced	NA	HEL: 209.9;HL-60: 167.0;HMC-1: 98.8;U-937: 115.3	Lung
SPOCK2	KIAA0275, testican-2	ENSG00000107742	SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2	10	72059035-72089032	Predicted secreted proteins	Evidence at protein level	HPA044605	Supported	NA	Uncertain	Nuclear speckles	Head and neck cancer:1.95e-5 (favourable), Breast cancer:4.05e-4 (favourable), Melanoma:4.72e-4 (favourable), Ovarian cancer:7.19e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	cerebral cortex: 161.8;lung: 127.8	lymph node: 75.1	Group enriched	8	Hep G2: 33.9;SCLC-21H: 79.9	Lung
ST8SIA6	SIAT8F	ENSG00000148488	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6	10	17318383-17454330	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011635, HPA072708	Uncertain	NA	Uncertain	Endoplasmic reticulum	NA	Tissue enhanced	Tissue enhanced	NA	breast: 13.4;lung: 18.1	epididymis: 9.1	Cell line enriched	8	HMC-1: 442.5	Lung
SUSD2	BK65A6.2, FLJ22778	ENSG00000099994	Sushi domain containing 2	22	24181259-24189110	Predicted membrane proteins	Evidence at protein level	HPA004117	Enhanced	NA	Approved	Plasma membrane	Renal cancer:3.29e-5 (unfavourable)	Expressed in all	Tissue enhanced	NA	lung: 139.3	small intestine: 35.2	Cell line enriched	33	SK-BR-3: 622.4	Lung
TBX2	NA	ENSG00000121068	T-box 2	17	61399896-61409466	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008586, CAB013636	Approved	NA	Approved	Nucleoplasm<br>Cytosol	NA	Expressed in all	Tissue enhanced	NA	lung: 50.0	seminal vesicle: 40.0	Cell line enhanced	NA	AN3-CA: 124.2;MCF7: 62.0;SH-SY5Y: 65.7;WM-115: 44.0	Lung
TLR8	CD288	ENSG00000101916	Toll like receptor 8	X	12906620-12923169	CD markers, Predicted membrane proteins	Evidence at protein level	HPA001608	Enhanced	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	appendix: 23.2;lung: 15.6;spleen: 18.3	lymph node: 6.6	Not detected	NA	NA	Lung
TMEM100	FLJ10970, FLJ37856	ENSG00000166292	Transmembrane protein 100	17	55719627-55732121	Predicted membrane proteins	Evidence at protein level	HPA055936	Approved	NA	Uncertain	Nucleoplasm	Liver cancer:2.67e-5 (favourable), Renal cancer:1.32e-4 (unfavourable)	Mixed	Tissue enhanced	NA	lung: 131.2;placenta: 78.3	epididymis: 44.5	Cell line enhanced	NA	ASC diff: 19.9;ASC TERT1: 13.7;HHSteC: 37.7;HSkMC: 15.0;U-87 MG: 13.6;WM-115: 11.8	Lung
TMEM125	MGC17299	ENSG00000179178	Transmembrane protein 125	1	43269994-43274002	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015796	NA	NA	Approved	Midbody<br>Cytosol	Renal cancer:2.91e-9 (favourable), Lung cancer:5.11e-5 (favourable)	Mixed	Tissue enhanced	NA	lung: 113.7	thyroid gland: 51.5	Cell line enhanced	NA	A-431: 23.4;BEWO: 21.1;CAPAN-2: 42.6;SK-BR-3: 31.0;T-47d: 31.2	Lung
TPSD1	NA	ENSG00000095917	Tryptase delta 1	16	1256059-1258998	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB002215, CAB032871, HPA040182, HPA049554	Supported	NA	Uncertain	Nuclear speckles	NA	Mixed	Tissue enhanced	NA	lung: 26.9	gallbladder: 20.3	Group enriched	46	HEL: 25.4;HMC-1: 36.4	Lung
TREM1	CD354, TREM-1	ENSG00000124731	Triggering receptor expressed on myeloid cells 1	6	41267926-41286719	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005563	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	appendix: 67.7;bone marrow: 63.0;lung: 103.1	adipose tissue: 26.9	Cell line enriched	11	U-87 MG: 24.5	Lung
TREM2	TREM-2, Trem2a, Trem2b, Trem2c	ENSG00000095970	Triggering receptor expressed on myeloid cells 2	6	41158506-41163186	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010917, HPA012571	Approved	NA	NA	NA	Liver cancer:4.24e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	cerebral cortex: 37.0;lung: 40.5	adrenal gland: 16.1	Cell line enhanced	NA	HBEC3-KT: 9.0;hTCEpi: 49.6;THP-1: 26.6	Lung
VEGFD	FIGF, VEGF-D	ENSG00000165197	Vascular endothelial growth factor D	X	15345591-15384376	Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA027342	Uncertain	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	breast: 25.0;lung: 59.3	adipose tissue: 13.2	Cell line enhanced	NA	ASC diff: 2.3;ASC TERT1: 2.0;HSkMC: 2.1	Lung
VEPH1	FLJ12604, KIAA1692	ENSG00000197415	Ventricular zone expressed PH domain containing 1	3	157259742-157533619	Predicted intracellular proteins	Evidence at protein level	HPA026645	Uncertain	NA	Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:7.75e-9 (favourable)	Mixed	Tissue enhanced	NA	adrenal gland: 26.6;kidney: 28.8;lung: 43.9	epididymis: 21.4	Cell line enhanced	NA	HUVEC TERT2: 204.2;TIME: 119.8	Lung
VIPR1	HVR1, RDC1, VPAC1, VPAC1R	ENSG00000114812	Vasoactive intestinal peptide receptor 1	3	42489299-42537573	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026777	Approved	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	lung: 60.0	duodenum: 34.4	Cell line enhanced	NA	CAPAN-2: 53.2;RT4: 34.8;WM-115: 77.3	Lung
XXbac-BPG116M5.17	NA	ENSG00000244255	NA	6	31927698-31952048	Predicted secreted proteins	Evidence at protein level	HPA000951, HPA001817, HPA001832	Approved	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	liver: 3.3;lung: 2.9	spleen: 1.2	Not detected	NA	NA	Lung
ZNF385B	FLJ25270, ZNF533	ENSG00000144331	Zinc finger protein 385B	2	179441982-179861505	Predicted intracellular proteins	Evidence at protein level	HPA046086	NA	NA	Supported	Nucleoli fibrillar center	Renal cancer:1.04e-9 (favourable), Breast cancer:4.86e-8 (favourable)	Group enriched	Tissue enhanced	NA	lung: 27.5	prostate: 20.0	Cell line enhanced	NA	Daudi: 12.3;HAP1: 32.8;U-698: 60.0	Lung
PIP	GCDFP-15, GCDFP15, GPIP4	ENSG00000159763	Prolactin induced protein	7	143132077-143139746	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002661, HPA009177	Enhanced	NA	NA	NA	Renal cancer:5.96e-5 (favourable)	Tissue enriched	Group enriched	618	breast: 4504.1;salivary gland: 6904.2;seminal vesicle: 4198.4	cervix, uterine: 8.4	Cell line enriched	415	T-47d: 649.3	Breast
LALBA	LYZL7	ENSG00000167531	Lactalbumin alpha	12	48567684-48570066	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB026343, HPA029855, HPA029856	Supported	NA	NA	NA	NA	Tissue enriched	Tissue enriched	566	breast: 2476.8	testis: 4.3	Not detected	NA	NA	Breast
CSN2	CASB	ENSG00000135222	Casein beta	4	69955256-69961007	Predicted secreted proteins	Evidence at protein level	HPA041036	Supported	NA	NA	NA	NA	Tissue enriched	Tissue enriched	348	breast: 347.6	salivary gland: 0.9	Not detected	NA	NA	Breast
SULT1C3	NA	ENSG00000196228	Sulfotransferase family 1C member 3	2	108247195-108265351	Enzymes, Predicted intracellular proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enriched	142	breast: 450.3	duodenum: 3.1	Not detected	NA	NA	Breast
DCD	AIDD, DCD-1, DSEP, HCAP, PIF	ENSG00000161634	Dermcidin	12	54644591-54648493	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA063967	Supported	NA	NA	NA	NA	Tissue enriched	Tissue enriched	96	breast: 336.4	skeletal muscle: 3.5	Not detected	NA	NA	Breast
CSN1S1	CASA, CSN1	ENSG00000126545	Casein alpha s1	4	69931081-69946574	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035659, HPA057031	Enhanced	NA	NA	NA	NA	Tissue enriched	Tissue enriched	85	breast: 1600.9	adipose tissue: 18.9	Not detected	NA	NA	Breast
ACSM1	BUCS1, MACS1	ENSG00000166743	Acyl-CoA synthetase medium-chain family member 1	16	20623237-20698890	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046291	Uncertain	NA	NA	NA	NA	Group enriched	Tissue enriched	49	breast: 298.7	prostate: 6.0	Group enriched	11	K-562: 3.2;NTERA-2: 15.6	Breast
BTN1A1	BT, BTN, BTN1	ENSG00000124557	Butyrophilin subfamily 1 member A1	6	26501221-26510422	Predicted membrane proteins	Evidence at protein level	HPA011126, CAB037340	Supported	NA	NA	NA	NA	Tissue enhanced	Tissue enriched	49	breast: 36.8	lymph node,tonsil: 0.7	Cell line enriched	5	CACO-2: 3.8	Breast
MUCL1	SBEM	ENSG00000172551	Mucin like 1	12	54830519-54858393	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039093	Enhanced	NA	NA	NA	NA	Tissue enriched	Tissue enriched	43	breast: 3798.1	salivary gland: 89.1	Cell line enhanced	NA	MCF7: 1.5;SK-BR-3: 3.5	Breast
KRT71	K6IRS1, KRT6IRS, KRT6IRS1	ENSG00000139648	Keratin 71	12	52543909-52553147	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049404	Supported	NA	NA	NA	NA	Tissue enhanced	Group enriched	34	breast: 1.4;epididymis: 5.3	all non-specific tissues: 0.0	Cell line enriched	11	CACO-2: 5.1	Breast
DGAT2L6	DC3, FLJ25989	ENSG00000184210	Diacylglycerol O-acyltransferase 2 like 6	X	70177483-70205545	Predicted membrane proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Group enriched	22	breast: 2.8;skin: 1.6	all non-specific tissues: 0.0	Not detected	NA	NA	Breast
SLCO1B7	LST3, SLC21A21	ENSG00000205754	Solute carrier organic anion transporter family member 1B7 (putative)	12	21015696-21092745	Predicted membrane proteins	Evidence at transcript level	HPA050892	Uncertain	NA	NA	NA	NA	Not detected	Tissue enriched	17	breast: 43.2	liver: 2.4	Cell line enhanced	NA	A-431: 2.3;A549: 1.6;CAPAN-2: 1.6;HeLa: 1.1;U-2 OS: 1.3	Breast
UGT2B11	NA	ENSG00000213759	UDP glucuronosyltransferase family 2 member B11	4	69199951-69214731	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA045108	Uncertain	NA	NA	NA	NA	Group enriched	Tissue enriched	17	breast: 320.4	gallbladder: 18.3	Not detected	NA	NA	Breast
ANKRD30A	NY-BR-1	ENSG00000148513	Ankyrin repeat domain 30A	10	37125788-37384111	Predicted intracellular proteins	Evidence at protein level	HPA071849	NA	NA	NA	NA	NA	Tissue enriched	Tissue enriched	15	breast: 49.8	testis: 3.3	Group enriched	34	A549: 2.4;U-266/70: 8.1	Breast
KRT25	KRT25A	ENSG00000204897	Keratin 25	17	40748021-40755332	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053977, HPA058943	Enhanced	NA	Approved	Vesicles	NA	Not detected	Group enriched	15	breast: 3.6;testis: 1.6	smooth muscle: 0.1	Cell line enriched	5	RPTEC TERT1: 1.0	Breast
CHIT1	CHI3, CHIT	ENSG00000133063	Chitinase 1	1	203212827-203273641	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA010575	Approved	NA	NA	NA	Cervical cancer:2.02e-4 (favourable)	Tissue enhanced	Group enriched	14	bone marrow: 31.3;breast: 10.9;cervix, uterine: 13.5;lung: 53.2;lymph node: 21.0	prostate,thyroid gland: 1.8	Not detected	NA	NA	Breast
FAM25C	bA164N7.4	ENSG00000276430	Family with sequence similarity 25 member C	10	47995355-47999791	Predicted intracellular proteins	Evidence at transcript level	HPA044808	Uncertain	NA	NA	NA	NA	Tissue enhanced	Group enriched	14	breast: 5.3;esophagus: 4.0;skin: 9.0;small intestine: 4.3;tonsil: 2.1	skeletal muscle,testis: 0.3	Cell line enriched	5	SK-BR-3: 12.1	Breast
AKR1B15	NA	ENSG00000227471	Aldo-keto reductase family 1 member B15	7	134549136-134579875	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020280, HPA073633	Uncertain	NA	Supported	Plasma membrane<br>Cytosol	Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Head and neck cancer:8.36e-4 (favourable)	Mixed	Tissue enriched	13	breast: 179.9	duodenum: 13.7	Group enriched	8	A549: 14.3;HDLM-2: 11.8;Hep G2: 7.6;NTERA-2: 3.2;SK-BR-3: 3.8;U-87 MG: 6.4	Breast
CSN3	CSN10	ENSG00000171209	Casein kappa	4	70242588-70251428	Predicted secreted proteins	Evidence at protein level	HPA035953, HPA035954	Enhanced	NA	NA	NA	NA	Group enriched	Tissue enriched	13	breast: 428.0	salivary gland: 32.0	Not detected	NA	NA	Breast
EN1	NA	ENSG00000163064	Engrailed homeobox 1	2	118842171-118847678	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB014884, HPA073141	Approved	NA	Supported	Nucleus<br>Nucleoli	NA	Tissue enhanced	Group enriched	13	adipose tissue: 1.3;breast: 1.0;lymph node: 1.9;skeletal muscle: 4.7;skin: 2.2	testis: 0.1	Cell line enhanced	NA	ASC diff: 10.8;fHDF/TERT166: 10.2;HSkMC: 9.7;PC-3: 7.1;U-138 MG: 9.6;U-2197: 10.2	Breast
FABP7	B-FABP, BLBP	ENSG00000164434	Fatty acid binding protein 7	6	122779475-122784074	Predicted intracellular proteins	Evidence at protein level	CAB025488, HPA028825, CAB058697	Enhanced	NA	NA	NA	Renal cancer:1.65e-6 (unfavourable), Breast cancer:2.49e-4 (favourable)	Group enriched	Group enriched	13	breast: 33.1;cerebral cortex: 102.3	skin: 5.2	Group enriched	8	AF22: 75.1;U-251 MG: 17.6;WM-115: 45.7	Breast
OXTR	NA	ENSG00000180914	Oxytocin receptor	3	8750408-8769628	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	NA	NA	NA	NA	NA	NA	Mixed	Tissue enriched	13	breast: 65.4	fallopian tube: 4.9	Cell line enhanced	NA	BJ: 357.1;BJ hTERT+: 104.6;BJ hTERT+ SV40 Large T+: 111.8;fHDF/TERT166: 330.6	Breast
RP11-545J16.1	NA	ENSG00000257046	NA	12	20815674-21090245	Predicted membrane proteins	Evidence at transcript level	HPA050892	Uncertain	NA	NA	NA	NA	Not detected	Tissue enriched	13	breast: 26.9	liver: 2.0	Cell line enhanced	NA	A-431: 1.4;CAPAN-2: 1.4;HeLa: 1.8	Breast
C10orf90	bA422P15.2, FATS, FLJ32938	ENSG00000154493	Chromosome 10 open reading frame 90	10	126424997-126670446	Predicted intracellular proteins	Evidence at protein level	HPA038648, HPA057599	Uncertain	NA	Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	NA	Tissue enriched	Group enriched	12	breast: 5.6;cerebral cortex: 15.3;salivary gland: 4.3;testis: 12.1	adipose tissue,skin: 0.7	Group enriched	9	SK-MEL-30: 94.3;U-2197: 33.5;U-266/84: 18.9;U-87 MG: 36.2;WM-115: 29.4	Breast
CST9	CLM, CTES7A	ENSG00000173335	Cystatin 9	20	23602410-23605876	Predicted secreted proteins	Evidence at transcript level	HPA029190	Uncertain	NA	NA	NA	NA	Tissue enriched	Tissue enriched	12	breast: 2.1	kidney: 0.1	Not detected	NA	NA	Breast
SERHL2	NA	ENSG00000183569	Serine hydrolase-like 2	22	42553617-42574382	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Group enriched	Tissue enriched	12	breast: 558.7	epididymis: 45.4	Cell line enriched	9	SK-BR-3: 207.3	Breast
UGT2B28	NA	ENSG00000135226	UDP glucuronosyltransferase family 2 member B28	4	69280499-69295050	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain	NA	NA	NA	NA	Tissue enriched	Tissue enriched	12	breast: 267.2	gallbladder: 21.5	Group enriched	9	Daudi: 2.1;NB-4: 1.7	Breast
ABCC11	MRP8	ENSG00000121270	ATP binding cassette subfamily C member 11	16	48166910-48247568	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031980, HPA031981, HPA031982, CAB032513	Uncertain	NA	NA	NA	NA	Group enriched	Tissue enriched	11	breast: 64.4	prostate: 6.0	Cell line enriched	5	T-47d: 64.4	Breast
GPR88	NA	ENSG00000181656	G protein-coupled receptor 88	1	100538137-100542018	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at transcript level	HPA007488	NA	Approved	NA	NA	NA	Tissue enriched	Group enriched	11	breast: 9.4;cerebral cortex: 3.1;liver: 4.9;ovary: 3.1;parathyroid gland: 4.9;spleen: 14.4	prostate: 0.6	Group enriched	8	HSkMC: 1.1;SCLC-21H: 2.3	Breast
ATP6V1B1	ATP6B1, RTA1B, VATB, Vma2, VPP3	ENSG00000116039	ATPase H+ transporting V1 subunit B1	2	70935882-70965406	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009523, HPA031847	Enhanced	NA	Approved	Nucleus<br>Nuclear membrane	NA	Group enriched	Group enriched	10	breast: 16.1;cervix, uterine: 47.9;fallopian tube: 21.1;kidney: 64.8;placenta: 27.8;salivary gland: 66.5	skin: 4.2	Group enriched	6	BEWO: 20.0;HaCaT: 17.4;SK-BR-3: 34.9	Breast
C6orf223	MGC45491	ENSG00000181577	Chromosome 6 open reading frame 223	6	44000580-44005958	Predicted intracellular proteins	Evidence at transcript level	HPA035765, HPA046117	Uncertain	NA	Approved	Nucleoli fibrillar center	Renal cancer:9.38e-5 (unfavourable), Liver cancer:4.59e-4 (unfavourable)	Mixed	Group enriched	10	breast: 22.7;lung: 5.6	duodenum: 1.3	Cell line enhanced	NA	A-431: 21.4;RPTEC TERT1: 25.1;THP-1: 9.6	Breast
OPRPN	BPLP, PRL1, PROL1	ENSG00000171199	Opiorphin prepropeptide	4	70397882-70410194	Predicted secreted proteins	Evidence at protein level	HPA065711	Approved	NA	NA	NA	NA	Tissue enhanced	Group enriched	10	breast: 33.1;salivary gland: 18.9	epididymis: 2.5	Not detected	NA	NA	Breast
DHRS2	HEP27, SDR25C1	ENSG00000100867	Dehydrogenase/reductase 2	14	23630115-23645639	Predicted intracellular proteins	Evidence at protein level	HPA053915, HPA069551	Enhanced	NA	Enhanced	Nucleus<br>Mitochondria	Renal cancer:3.75e-5 (unfavourable), Endometrial cancer:3.23e-4 (unfavourable), Urothelial cancer:6.45e-4 (favourable)	Tissue enriched	Group enriched	9	breast: 436.3;urinary bladder: 339.0	salivary gland: 40.8	Cell line enhanced	NA	Hep G2: 476.9;RT4: 659.6;SK-BR-3: 2967.1;U-2 OS: 1332.4	Breast
KRT79	K6L, KRT6L	ENSG00000185640	Keratin 79	12	52821410-52834295	Predicted intracellular proteins	Evidence at protein level	HPA059347	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	9	breast: 4.0;skin: 17.1	esophagus: 1.1	Cell line enriched	18	HMC-1: 375.1	Breast
SCGB1D2	LIPB, LPHB	ENSG00000124935	Secretoglobin family 1D member 2	11	62242210-62244808	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA035318	Approved	NA	NA	NA	Endometrial cancer:3.46e-6 (favourable), Renal cancer:8.03e-6 (favourable)	Group enriched	Group enriched	9	breast: 1446.3;cervix, uterine: 5193.3	epididymis: 385.3	Cell line enriched	7	SCLC-21H: 11.2	Breast
C5orf46	MGC23985, SSSP1	ENSG00000178776	Chromosome 5 open reading frame 46	5	147880726-147906538	Predicted secreted proteins	Evidence at transcript level	HPA058999	NA	NA	Approved	Nuclear speckles<br>Mitochondria	Renal cancer:1.75e-9 (unfavourable), Cervical cancer:3.98e-4 (unfavourable)	Tissue enhanced	Group enriched	8	breast: 17.6;salivary gland: 77.2;skin: 62.4;testis: 19.9	heart muscle: 5.8	Cell line enhanced	NA	PC-3: 83.2;SiHa: 21.5;U-2 OS: 59.9;U-251 MG: 19.3	Breast
ESR1	Era, ESR, NR3A1	ENSG00000091831	Estrogen receptor 1	6	151656691-152129619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000037, HPA000449, HPA000450, CAB055099, CAB072858	Enhanced	NA	Approved	Nucleus<br>Vesicles	Endometrial cancer:5.47e-7 (favourable)	Group enriched	Group enriched	8	breast: 37.6;cervix, uterine: 127.8;endometrium: 180.8;fallopian tube: 106.4;smooth muscle: 76.5	seminal vesicle: 13.5	Group enriched	11	MCF7: 34.7;T-47d: 53.2	Breast
PAX3	HUP2, WS1	ENSG00000135903	Paired box 3	2	222199888-222298996	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063659, HPA069000	Approved	NA	Supported	Nucleoplasm	NA	Tissue enriched	Group enriched	8	breast: 1.2;skeletal muscle: 1.1;skin: 3.2;testis: 2.4	prostate: 0.2	Cell line enhanced	NA	BJ hTERT+ SV40 Large T+: 9.6;BJ hTERT+ SV40 Large T+ RasG12V: 11.6;RH-30: 16.2;SK-MEL-30: 24.6	Breast
SYCP2	SCP2	ENSG00000196074	Synaptonemal complex protein 2	20	59863563-59933655	Predicted intracellular proteins	Evidence at protein level	HPA062401, HPA065613	NA	NA	Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	NA	Group enriched	Group enriched	8	breast: 17.7;testis: 76.9	prostate: 6.0	Cell line enhanced	NA	MOLT-4: 43.5;SiHa: 97.9;T-47d: 77.3	Breast
AP000322.53	NA	ENSG00000243627	NA	21	34418715-34423966	Predicted membrane proteins	Evidence at transcript level	HPA029085	Uncertain	NA	NA	NA	NA	Not detected	Group enriched	7	breast: 1.5;fallopian tube: 1.4;kidney: 4.3	skin: 0.3	Not detected	NA	NA	Breast
APOD	NA	ENSG00000189058	Apolipoprotein D	3	195568702-195584205	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040520	Enhanced	NA	Approved	Plasma membrane	Thyroid cancer:4.12e-4 (unfavourable), Breast cancer:5.51e-4 (favourable), Stomach cancer:6.02e-4 (unfavourable)	Expressed in all	Tissue enriched	7	breast: 4620.2	adipose tissue: 670.2	Cell line enhanced	NA	ASC diff: 1866.1;ASC TERT1: 1018.4;WM-115: 301.1	Breast
ARHGAP40	C20orf95, dJ1100H13.4	ENSG00000124143	Rho GTPase activating protein 40	20	38601934-38651035	Predicted intracellular proteins	Evidence at protein level	HPA042636, HPA042840	Uncertain	NA	Supported	Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:2.89e-4 (unfavourable)	Mixed	Group enriched	7	breast: 38.1;epididymis: 43.7;esophagus: 12.6;seminal vesicle: 11.3;skin: 53.8	prostate: 4.4	Cell line enhanced	NA	BEWO: 8.0;HBEC3-KT: 9.7;RPTEC TERT1: 8.8;SK-BR-3: 9.5;T-47d: 14.4	Breast
CARD18	ICEBERG, pseudo-ICE, UNQ5804	ENSG00000255501	Caspase recruitment domain family member 18	11	105137721-105139726	Predicted intracellular proteins	Evidence at protein level	HPA038582	Approved	NA	NA	NA	NA	Tissue enhanced	Group enriched	7	breast: 10.6;skin: 29.7	esophagus: 3.0	Cell line enhanced	NA	BEWO: 3.0;hTCEpi: 1.9;U-2 OS: 2.9	Breast
CH507-396I9.3	NA	ENSG00000278961	NA	21	7788703-7793954	Predicted membrane proteins	Evidence at transcript level	HPA029085	Uncertain	NA	NA	NA	NA	Not detected	Group enriched	7	breast: 1.5;fallopian tube: 1.4;kidney: 4.3	skin: 0.3	Not detected	NA	NA	Breast
GSTT2B	GSTT2P	ENSG00000133433	Glutathione S-transferase theta 2B (gene/pseudogene)	22	23957414-23961186	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000750	Uncertain	NA	Supported	Nucleoplasm<br>Cytosol	Breast cancer:5.06e-4 (favourable)	Expressed in all	Tissue enriched	7	breast: 411.1	adrenal gland: 60.8	Cell line enhanced	NA	AN3-CA: 53.0;HHSteC: 68.3;T-47d: 60.4	Breast
KRT15	CK15, K15, K1CO	ENSG00000171346	Keratin 15	17	41513743-41522529	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023910, HPA024554	Enhanced	NA	Supported	Nucleoplasm<br>Intermediate filaments	Breast cancer:4.50e-4 (favourable)	Tissue enhanced	Group enriched	7	breast: 321.5;esophagus: 784.4;skin: 1010.3	prostate: 94.7	Group enriched	12	HaCaT: 732.6;hTCEpi: 454.1	Breast
KRTAP21-1	KAP21.1	ENSG00000187005	Keratin associated protein 21-1	21	30754830-30755428	Predicted intracellular proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Not detected	Group enriched	7	breast: 13.5;testis: 6.0	seminal vesicle: 1.3	Cell line enhanced	NA	SK-MEL-30: 1.2	Breast
SCGB2A2	MGB1, MGC71974, UGB2	ENSG00000110484	Secretoglobin family 2A member 2	11	62270155-62273156	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB026270	Supported	NA	NA	NA	Endometrial cancer:9.57e-8 (favourable)	Tissue enriched	Tissue enriched	7	breast: 3687.7	cervix, uterine: 507.6	Cell line enriched	95	SK-BR-3: 13.3	Breast
SPINK8	NA	ENSG00000229453	Serine peptidase inhibitor, Kazal type 8 (putative)	3	48306842-48328341	Predicted secreted proteins	Evidence at transcript level	HPA053151	Uncertain	NA	NA	NA	Breast cancer:8.47e-4 (unfavourable)	Group enriched	Tissue enriched	7	breast: 58.2	bone marrow: 7.7	Cell line enriched	49	SK-BR-3: 55.0	Breast
TBX15	TBX14	ENSG00000092607	T-box 15	1	118883046-118989556	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052245, HPA053713	Uncertain	NA	Approved	Nucleoplasm<br>Centrosome	Renal cancer:5.57e-8 (unfavourable)	Mixed	Group enriched	7	adipose tissue: 17.0;breast: 8.9;liver: 24.1;skeletal muscle: 42.2	lymph node: 3.1	Cell line enhanced	NA	ASC diff: 36.8;BJ hTERT+ SV40 Large T+ RasG12V: 20.9;fHDF/TERT166: 22.5;HSkMC: 28.3;RH-30: 29.4;U-2197: 26.3	Breast
ABCA12	DKFZP434G232, ICR2B, LI2	ENSG00000144452	ATP binding cassette subfamily A member 12	2	214931542-215138428	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA078239	NA	NA	Approved	Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol	NA	Mixed	Group enriched	6	breast: 7.7;skin: 25.2	tonsil: 2.5	Group enriched	6	hTCEpi: 28.4;SK-BR-3: 13.8;T-47d: 9.1	Breast
ALDH3B2	ALDH8	ENSG00000132746	Aldehyde dehydrogenase 3 family member B2	11	67662162-67681200	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045132	Enhanced	NA	NA	NA	NA	Mixed	Group enriched	6	breast: 89.9;esophagus: 103.4;skin: 122.2	tonsil: 19.0	Cell line enhanced	NA	MCF7: 49.6;SK-BR-3: 48.3;T-47d: 12.2	Breast
GLRA3	NA	ENSG00000145451	Glycine receptor alpha 3	4	174636914-174829314	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Group enriched	6	breast: 2.6;cerebral cortex: 9.1	adrenal gland: 1.0	Cell line enhanced	NA	Karpas-707: 1.4	Breast
GLYATL1P3	NA	ENSG00000255151	Glycine-N-acyltransferase like 1 pseudogene 3	11	59086307-59094786	Predicted intracellular proteins	Evidence at protein level	HPA039501	Uncertain	NA	Uncertain	Golgi apparatus<br>Cytosol	NA	Tissue enhanced	Group enriched	6	breast: 9.7;lymph node: 3.4	appendix,prostate: 1.1	Cell line enhanced	NA	Daudi: 1.3;T-47d: 1.1;U-266/70: 1.4	Breast
GLYATL2	BXMAS2-10, MGC24009	ENSG00000156689	Glycine-N-acyltransferase like 2	11	58834065-58904215	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060292, HPA065454	Uncertain	NA	Approved	Mitochondria	Endometrial cancer:9.05e-7 (favourable)	Tissue enhanced	Group enriched	6	breast: 14.3;cervix, uterine: 27.5;gallbladder: 11.0	salivary gland: 3.0	Cell line enhanced	NA	BJ hTERT+: 4.1;HAP1: 5.9;SK-BR-3: 10.2;U-2197: 6.0	Breast
GSTM5	NA	ENSG00000134201	Glutathione S-transferase mu 5	1	109712255-109775428	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048652, HPA055972, HPA055973	Approved	NA	Approved	Cytokinetic bridge<br>Cytosol	NA	Mixed	Group enriched	6	breast: 845.2;ovary: 221.0	fallopian tube: 84.6	Group enriched	8	fHDF/TERT166: 12.9;HHSteC: 5.7;HSkMC: 5.3	Breast
LGALS7	GAL7, LGALS7A, PIG1, TP53I1	ENSG00000205076	Galectin 7	19	38770971-38773492	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001549, CAB032606	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	6	breast: 18.1;esophagus: 24.3;skin: 27.7	skeletal muscle: 3.6	Cell line enhanced	NA	HaCaT: 6.2;SCLC-21H: 1.2	Breast
SCGB3A1	HIN-1, HIN1, LU105, PnSP-2, UGRP2	ENSG00000161055	Secretoglobin family 3A member 1	5	180590103-180591540	Plasma proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Group enriched	Group enriched	6	breast: 125.3;cervix, uterine: 345.8;lung: 301.1;salivary gland: 193.1	stomach: 40.9	Cell line enhanced	NA	NB-4: 1.3	Breast
SDR16C5	EPHD-2, RDH-E2, RDHE2	ENSG00000170786	Short chain dehydrogenase/reductase family 16C member 5	8	56300010-56320776	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA025224	Enhanced	NA	NA	NA	Head and neck cancer:7.88e-4 (favourable)	Mixed	Group enriched	6	breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3	cervix, uterine: 5.6	Cell line enhanced	NA	CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2	Breast
STAC2	24b2	ENSG00000141750	SH3 and cysteine rich domain 2	17	39210536-39225872	Predicted intracellular proteins	Evidence at protein level	HPA017288	NA	NA	Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:4.05e-5 (unfavourable), Glioma:5.04e-4 (unfavourable), Ovarian cancer:6.66e-4 (unfavourable)	Group enriched	Group enriched	6	breast: 32.0;cerebral cortex: 30.1;epididymis: 13.8;seminal vesicle: 35.6	skin: 4.5	Cell line enhanced	NA	HeLa: 22.2;hTEC/SVTERT24-B: 4.8;U-87 MG: 14.4	Breast
TTC6	C14orf25, NCRNA00291	ENSG00000139865	Tetratricopeptide repeat domain 6	14	37595847-38041442	Predicted intracellular proteins	Evidence at protein level	HPA069293	NA	NA	Approved	Centrosome	NA	Group enriched	Group enriched	6	breast: 10.5;prostate: 28.3;testis: 10.4	stomach: 2.6	Cell line enhanced	NA	Hep G2: 5.7;MCF7: 9.4;RT4: 6.7;T-47d: 21.4	Breast
AKR1C2	BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD	ENSG00000151632	Aldo-keto reductase family 1 member C2	10	4987400-5018031	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB047304, HPA068265	Enhanced	NA	Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol	NA	Group enriched	Group enriched	5	adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0	duodenum: 29.8	Cell line enhanced	NA	A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6	Breast
MMP27	NA	ENSG00000137675	Matrix metallopeptidase 27	11	102691487-102705806	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA069097	Approved	NA	NA	NA	NA	Not detected	Group enriched	5	breast: 6.0;skin: 2.8	bone marrow: 0.8	Not detected	NA	NA	Breast
MYEOV	OCIM	ENSG00000172927	Myeloma overexpressed	11	69294138-69367726	Predicted membrane proteins	Evidence at transcript level	HPA012949	Uncertain	NA	Approved	Nucleus<br>Vesicles	Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable)	Mixed	Group enriched	5	adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 6.8	appendix: 1.0	Cell line enhanced	NA	A-431: 154.1;A549: 74.9;U-2 OS: 38.7	Breast
ALOX15B	15-LOX-2	ENSG00000179593	Arachidonate 15-lipoxygenase, type B	17	8039017-8049134	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010562	Enhanced	NA	Supported	Plasma membrane<br>Cytosol	NA	Expressed in all	Tissue enhanced	NA	breast: 145.0;prostate: 115.3	lung: 26.1	Group enriched	15	HHSteC: 6.5;HSkMC: 11.9;hTCEpi: 25.0	Breast
ALX4	FPP, KIAA1788, PFM, PFM2	ENSG00000052850	ALX homeobox 4	11	44260444-44310166	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001903	NA	NA	Supported	Nucleoplasm	NA	Tissue enhanced	Tissue enhanced	NA	breast: 2.2	endometrium,testis: 1.0	Cell line enhanced	NA	AN3-CA: 3.7;BJ: 2.8;HAP1: 4.8;HEK93: 4.4;HEL: 6.0;K-562: 2.8;SiHa: 7.4	Breast
APCDD1L	FLJ90166	ENSG00000198768	APC down-regulated 1 like	20	58459101-58515131	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067015	Uncertain	NA	Uncertain	Mitochondria	NA	Mixed	Tissue enhanced	NA	breast: 6.5;salivary gland: 11.6	kidney: 2.9	Cell line enhanced	NA	fHDF/TERT166: 88.4;hTEC/SVTERT24-B: 39.4;HUVEC TERT2: 33.7;TIME: 65.0;U-87 MG: 47.5	Breast
ARHGEF38	FLJ20184	ENSG00000236699	Rho guanine nucleotide exchange factor 38	4	105552620-105708093	Predicted intracellular proteins	Evidence at protein level	HPA036510, HPA045484	Uncertain	NA	Approved	Nucleoplasm<br>Centrosome	NA	Tissue enhanced	Tissue enhanced	NA	breast: 10.0;prostate: 9.3	epididymis: 6.8	Group enriched	8	RPTEC TERT1: 11.0;SK-BR-3: 6.0;T-47d: 7.9	Breast
ATP13A5	FLJ16025	ENSG00000187527	ATPase 13A5	3	193274790-193378843	Predicted membrane proteins	Evidence at transcript level	HPA031771, HPA031774	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	breast: 17.7	salivary gland: 3.9	Cell line enhanced	NA	SK-BR-3: 1.2	Breast
AWAT2	DGAT2L4, MFAT	ENSG00000147160	Acyl-CoA wax alcohol acyltransferase 2	X	70040542-70049938	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA062748	Approved	NA	NA	NA	NA	Tissue enriched	Tissue enhanced	NA	breast: 2.0;skin: 1.2	testis: 0.5	Not detected	NA	NA	Breast
AZGP1	ZA2G, ZAG	ENSG00000160862	Alpha-2-glycoprotein 1, zinc-binding	7	99966720-99976157	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012582, CAB016087, CAB032276	Enhanced	NA	NA	NA	Renal cancer:1.53e-4 (favourable), Liver cancer:2.90e-4 (favourable)	Group enriched	Tissue enhanced	NA	breast: 1201.5;liver: 1272.1;prostate: 1490.2;salivary gland: 1423.5	kidney: 294.4	Cell line enhanced	NA	Hep G2: 33.7;RPMI-8226: 79.5;T-47d: 35.0	Breast
C1orf64	ERRF, MGC24047	ENSG00000183888	Chromosome 1 open reading frame 64	1	16004236-16008807	Predicted intracellular proteins	Evidence at transcript level	HPA026676	Uncertain	NA	Approved	Nucleoplasm	Endometrial cancer:1.68e-6 (favourable)	Tissue enhanced	Tissue enhanced	NA	breast: 6.8	cervix, uterine: 3.3	Group enriched	9	Hep G2: 5.3;SK-BR-3: 10.1;T-47d: 4.1	Breast
C2orf82	ASCL830, UNQ830	ENSG00000182600	Chromosome 2 open reading frame 82	2	232857270-232878708	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA052824	Uncertain	NA	Approved	Nucleus<br>Nucleoli	Endometrial cancer:3.56e-4 (unfavourable)	Mixed	Tissue enhanced	NA	breast: 5.1;testis: 4.1	cerebral cortex: 2.6	Cell line enriched	13	Hep G2: 40.1	Breast
CCL28	CCK1, MEC, SCYA28	ENSG00000151882	C-C motif chemokine ligand 28	5	43376645-43412391	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA077434	Supported	NA	NA	NA	Pancreatic cancer:1.43e-4 (unfavourable)	Mixed	Tissue enhanced	NA	breast: 71.1;salivary gland: 126.0	thyroid gland: 38.0	Cell line enhanced	NA	EFO-21: 12.1;SiHa: 31.8;SK-MEL-30: 12.9;T-47d: 37.8	Breast
CLDN8	NA	ENSG00000156284	Claudin 8	21	30214006-30216073	Predicted membrane proteins, Transporters	Evidence at protein level	HPA060605	Supported	NA	NA	NA	Renal cancer:3.32e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	breast: 84.9;kidney: 76.1;rectum: 56.0	thyroid gland: 37.3	Cell line enriched	17	HaCaT: 30.1	Breast
CLEC3A	CLECSF1	ENSG00000166509	C-type lectin domain family 3 member A	16	78022515-78066761	Predicted secreted proteins	Evidence at protein level	HPA051511	Uncertain	NA	NA	NA	Breast cancer:1.61e-4 (unfavourable)	Tissue enriched	Tissue enhanced	NA	breast: 12.4;urinary bladder: 8.3	prostate: 3.3	Cell line enhanced	NA	MCF7: 2.5;SK-BR-3: 5.5;T-47d: 19.7	Breast
CMA1	NA	ENSG00000092009	Chymase 1	14	24505353-24508265	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000363, HPA052634	Enhanced	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	breast: 23.8	esophagus: 11.4	Not detected	NA	NA	Breast
CYP4Z1	CYP4A20	ENSG00000186160	Cytochrome P450 family 4 subfamily Z member 1	1	47067488-47118319	Enzymes, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enriched	Tissue enhanced	NA	breast: 6.9	lung: 1.5	Group enriched	43	HDLM-2: 8.5;SK-BR-3: 2.8	Breast
DUSP4	HVH2, MKP-2, TYP	ENSG00000120875	Dual specificity phosphatase 4	8	29333064-29350668	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061967	NA	NA	Supported	Nucleoplasm	Renal cancer:4.19e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	breast: 29.6	stomach: 28.2	Cell line enhanced	NA	A549: 90.3;SK-MEL-30: 120.4;WM-115: 120.9	Breast
EFHD1	FLJ13612	ENSG00000115468	EF-hand domain family member D1	2	232606057-232682781	Predicted intracellular proteins	Evidence at protein level	HPA049331, HPA056959	Enhanced	NA	Supported	Nucleoli fibrillar center<br>Golgi apparatus	Renal cancer:2.93e-7 (favourable)	Expressed in all	Tissue enhanced	NA	breast: 227.6	kidney: 177.3	Group enriched	7	BEWO: 121.1;RPTEC TERT1: 51.3;SK-BR-3: 225.6;T-47d: 222.0	Breast
ELF5	NA	ENSG00000135374	E74 like ETS transcription factor 5	11	34478793-34513805	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062706	NA	NA	Supported	Nucleoplasm	Lung cancer:3.64e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	breast: 172.6;salivary gland: 64.2	seminal vesicle: 42.2	Group enriched	10	RT4: 24.0;T-47d: 53.3	Breast
ELOVL3	CIG-30	ENSG00000119915	ELOVL fatty acid elongase 3	10	102226328-102229589	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036236	Supported	NA	Approved	Vesicles<br>Cytosol	Endometrial cancer:6.25e-5 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	adipose tissue: 3.6;breast: 4.4;skin: 3.4	testis: 2.3	Cell line enhanced	NA	HSkMC: 10.4;SiHa: 24.5	Breast
FABP9	PERF, PERF15, T-FABP	ENSG00000205186	Fatty acid binding protein 9	8	81458341-81461579	Predicted intracellular proteins	Evidence at protein level	HPA073619	Approved	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	breast: 1.6	adipose tissue: 0.7	Not detected	NA	NA	Breast
FAM180B	LOC399888	ENSG00000196666	Family with sequence similarity 180 member B	11	47586693-47589194	Predicted intracellular proteins	Evidence at transcript level	HPA029408	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	breast: 6.9;skin: 4.4	adipose tissue: 4.1	Cell line enhanced	NA	SK-MEL-30: 1.8;U-937: 1.3	Breast
FAM196B	C5orf57	ENSG00000204767	Family with sequence similarity 196 member B	5	169864264-169980740	Predicted intracellular proteins	Evidence at transcript level	HPA047227	Uncertain	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	breast: 7.6;cerebral cortex: 7.0	ovary: 2.1	Cell line enhanced	NA	fHDF/TERT166: 30.1;HUVEC TERT2: 20.4;U-138 MG: 61.2	Breast
FOXI1	FKHL10, FREAC6	ENSG00000168269	Forkhead box I1	5	170105897-170109725	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071469	Enhanced	NA	Uncertain	Nucleoli<br>Vesicles	NA	Group enriched	Tissue enhanced	NA	breast: 10.4;kidney: 20.0	salivary gland: 6.2	Cell line enhanced	NA	MCF7: 1.2	Breast
GJC3	CX30.2, GJE1	ENSG00000176402	Gap junction protein gamma 3	7	99923269-99929620	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015024	Uncertain	NA	NA	NA	NA	Group enriched	Tissue enhanced	NA	breast: 8.7;prostate: 5.3	testis: 2.7	Cell line enhanced	NA	SK-MEL-30: 1.8;U-2197: 1.7	Breast
HIST1H2AE	H2A.1, H2A/a, H2AFA	ENSG00000277075	Histone cluster 1 H2A family member e	6	26216975-26217483	Predicted intracellular proteins	Evidence at protein level	CAB012242, HPA041189	Supported	NA	Supported	Nucleoplasm	NA	Expressed in all	Tissue enhanced	NA	breast: 54.1	prostate: 21.5	Cell line enhanced	NA	U-266/70: 28.2	Breast
HIST1H2BG	H2B.1A, H2B/a, H2BFA	ENSG00000273802	Histone cluster 1 H2B family member g	6	26215159-26216692	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported	NA	Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.70e-8 (unfavourable)	Expressed in all	Tissue enhanced	NA	breast: 17.5;prostate: 11.3	bone marrow: 4.6	Cell line enhanced	NA	SiHa: 11.2;T-47d: 19.9;U-266/70: 15.0	Breast
HIST1H4H	H4/h, H4FH	ENSG00000158406	Histone cluster 1 H4 family member h	6	26277609-26285638	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported	NA	NA	NA	Renal cancer:6.18e-6 (unfavourable), Liver cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	breast: 9.9	prostate: 6.3	Cell line enhanced	NA	U-266/84: 49.1	Breast
IL17B	IL-17B, IL-20, MGC138900, MGC138901, NIRF, ZCYTO7	ENSG00000127743	Interleukin 17B	5	149371324-149404202	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA042441	Uncertain	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	breast: 4.0	smooth muscle: 3.3	Cell line enhanced	NA	HEL: 1.2	Breast
IL22RA2	CRF2-S1, IL-22BP	ENSG00000164485	Interleukin 22 receptor subunit alpha 2	6	137143820-137173648	Predicted secreted proteins	Evidence at protein level	HPA030582, CAB034906	Uncertain	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	breast: 4.1;tonsil: 2.9	appendix: 1.9	Cell line enhanced	NA	U-937: 1.0	Breast
IRX1	IRX-5	ENSG00000170549	Iroquois homeobox 1	5	3596054-3601403	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043160	Uncertain	NA	Approved	Nucleoplasm<br>Golgi apparatus	NA	Group enriched	Tissue enhanced	NA	breast: 7.7;kidney: 5.3;salivary gland: 5.7	lung: 3.6	Cell line enhanced	NA	AF22: 9.8;REH: 38.0;U-251 MG: 13.8	Breast
IRX2	NA	ENSG00000170561	Iroquois homeobox 2	5	2745845-2751662	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050895, HPA054669	Approved	NA	Approved	Nucleus<br>Nucleoli	Pancreatic cancer:8.84e-4 (favourable)	Mixed	Tissue enhanced	NA	breast: 29.6;lung: 28.0	skin: 19.5	Cell line enhanced	NA	AF22: 100.0;BEWO: 58.5;hTCEpi: 47.9	Breast
IRX3	IRX-1	ENSG00000177508	Iroquois homeobox 3	16	54283304-54286763	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062522	NA	NA	Approved	Vesicles	NA	Expressed in all	Tissue enhanced	NA	breast: 96.6	skin: 70.5	Cell line enhanced	NA	NB-4: 129.5;RPTEC TERT1: 178.7;T-47d: 115.6;THP-1: 136.2	Breast
IRX5	IRX-2a	ENSG00000176842	Iroquois homeobox 5	16	54930862-54934485	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047130	NA	NA	Approved	Nuclear speckles<br>Microtubules<br>Cytosol	Lung cancer:4.59e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	breast: 17.9;lung: 9.6;skin: 10.1	salivary gland: 4.6	Cell line enhanced	NA	RPTEC TERT1: 20.1;T-47d: 34.4	Breast
KIT	C-Kit, CD117, PBT, SCFR	ENSG00000157404	KIT proto-oncogene receptor tyrosine kinase	4	54657918-54740715	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB003288, HPA004471, CAB068253, CAB072867, HPA073252	Enhanced	Supported	Supported	Plasma membrane	Renal cancer:5.63e-4 (favourable)	Mixed	Tissue enhanced	NA	breast: 133.6	thyroid gland: 78.7	Group enriched	14	HEL: 220.1;HMC-1: 434.1	Breast
KRT17	PCHC1	ENSG00000128422	Keratin 17	17	41619437-41624842	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000029, HPA000452, HPA000453, HPA000539, HPA045062	Enhanced	NA	Enhanced	Intermediate filaments	Breast cancer:4.44e-4 (favourable), Renal cancer:5.74e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	breast: 222.3;seminal vesicle: 226.0;urinary bladder: 322.8	prostate: 115.6	Group enriched	6	hTCEpi: 14378.7;SiHa: 8960.6	Breast
KRT27	KRT25C	ENSG00000171446	Keratin 27	17	40776808-40782534	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055114	Supported	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	breast: 1.3	skin,testis: 0.4	Cell line enhanced	NA	EFO-21: 1.3	Breast
KRT28	KRT25D	ENSG00000173908	Keratin 28	17	40792203-40799959	Predicted intracellular proteins	Evidence at protein level	HPA066890	Supported	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	breast: 1.0	testis: 0.4	Not detected	NA	NA	Breast
KRT81	Hb-1, KRTHB1	ENSG00000205426	Keratin 81	12	52285913-52291534	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049778	Supported	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	breast: 3.8	placenta: 1.5	Cell line enhanced	NA	A-431: 2684.9;A549: 2072.1;PC-3: 1009.2;U-251 MG: 1766.1	Breast
LGALS7B	GAL7	ENSG00000178934	Galectin 7B	19	38789211-38791749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001549, CAB025100	Supported	NA	NA	NA	Endometrial cancer:1.59e-4 (unfavourable)	Group enriched	Tissue enhanced	NA	breast: 10.4;esophagus: 19.3	skeletal muscle: 3.8	Cell line enriched	21	HaCaT: 3.7	Breast
LMX1B	NPS1	ENSG00000136944	LIM homeobox transcription factor 1 beta	9	126614443-126701032	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073716	NA	NA	Approved	Nucleus	NA	Tissue enriched	Tissue enhanced	NA	breast: 5.8;salivary gland: 11.2	testis: 2.2	Cell line enhanced	NA	MCF7: 13.7;T-47d: 10.1	Breast
MAB21L1	CAGR1	ENSG00000180660	Mab-21 like 1	13	35474182-35477209	Predicted intracellular proteins	Evidence at protein level	HPA049324, HPA059864	NA	NA	Enhanced	Nucleus<br>Cytosol	NA	Mixed	Tissue enhanced	NA	adrenal gland: 5.5;breast: 5.2	adipose tissue: 2.4	Cell line enhanced	NA	BJ: 29.7;BJ hTERT+ SV40 Large T+: 36.9;HBF TERT88: 41.4;SH-SY5Y: 135.2	Breast
MAP1LC3C	ATG8J	ENSG00000197769	Microtubule associated protein 1 light chain 3 gamma	1	241995490-241999073	Predicted intracellular proteins	Evidence at protein level	HPA072670	NA	NA	Supported	Cytoplasmic bodies	Endometrial cancer:1.34e-7 (unfavourable)	Mixed	Tissue enhanced	NA	breast: 12.7;placenta: 16.1	lung: 8.1	Cell line enhanced	NA	AF22: 6.0;ASC TERT1: 3.9;BEWO: 3.7;EFO-21: 3.2	Breast
MATN4	NA	ENSG00000124159	Matrilin 4	20	45293445-45308529	Plasma proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	breast: 3.0;pancreas: 5.9;skin: 3.5	cervix, uterine: 1.4	Cell line enhanced	NA	NB-4: 1.7;U-937: 1.0	Breast
MGP	NA	ENSG00000111341	Matrix Gla protein	12	14881181-14885926	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013949	Approved	NA	NA	NA	Renal cancer:4.15e-6 (unfavourable)	Expressed in all	Tissue enhanced	NA	breast: 4883.1	smooth muscle: 1900.4	Cell line enriched	5	AN3-CA: 9115.9	Breast
MIA	CD-RAP	ENSG00000261857	Melanoma inhibitory activity	19	40771648-40777490	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA031950, HPA042369	Supported	Supported	NA	NA	Breast cancer:2.08e-4 (favourable)	Tissue enriched	Tissue enhanced	NA	breast: 62.9;stomach: 50.0	salivary gland: 18.4	Group enriched	41	AN3-CA: 79.3;CAPAN-2: 63.4;SK-MEL-30: 198.0;WM-115: 233.6	Breast
MRGPRX2	MRGX2	ENSG00000183695	MAS related GPR family member X2	11	19054455-19060681	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA055220	Approved	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	breast: 1.2;skin: 1.2	cervix, uterine: 0.6	Not detected	NA	NA	Breast
MS4A18	NA	ENSG00000214782	Membrane spanning 4-domains A18	11	60729304-60744212	Predicted membrane proteins	Evidence at transcript level	HPA045121	Approved	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	breast: 10.3;duodenum: 23.9	small intestine: 4.0	Not detected	NA	NA	Breast
MYB	c-myb	ENSG00000118513	MYB proto-oncogene, transcription factor	6	135181315-135219173	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017704	Approved	NA	Approved	Nucleus<br>Plasma membrane	Prostate cancer:9.65e-4 (favourable), Stomach cancer:9.87e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	breast: 26.3;rectum: 29.1	colon: 25.2	Cell line enhanced	NA	HL-60: 173.9;MOLT-4: 321.7;REH: 222.8;THP-1: 230.7;U-937: 145.8	Breast
NPY2R	NA	ENSG00000185149	Neuropeptide Y receptor Y2	4	155208629-155217078	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	breast: 1.0;cerebral cortex: 1.7;testis: 1.0	rectum: 0.6	Cell line enriched	6	SH-SY5Y: 8.0	Breast
NQO1	DHQU, DIA4, DTD, NMOR1, QR1	ENSG00000181019	NAD(P)H quinone dehydrogenase 1	16	69706996-69726951	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007308, CAB012421	Enhanced	NA	Enhanced	Cytosol	Head and neck cancer:1.45e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	breast: 379.3;stomach: 556.0	gallbladder: 320.2	Expressed in all	NA	NA	Breast
OBP2B	hOBPIIb, LCN14	ENSG00000171102	Odorant binding protein 2B	9	133205277-133209250	Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Group enriched	Tissue enhanced	NA	breast: 1.8;testis: 6.8	fallopian tube: 1.4	Not detected	NA	NA	Breast
OXGR1	aKGR, GPR80, GPR99, P2RY15, P2Y15	ENSG00000165621	Oxoglutarate receptor 1	13	96985719-96994730	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA067673	NA	NA	Supported	Plasma membrane	NA	Mixed	Tissue enhanced	NA	breast: 5.1	kidney: 4.6	Cell line enhanced	NA	RT4: 2.6;SK-BR-3: 1.1;U-2 OS: 1.7	Breast
PNLIPRP3	NA	ENSG00000203837	Pancreatic lipase related protein 3	10	116427867-116477957	Enzymes, Predicted secreted proteins	Evidence at transcript level	HPA046202, HPA052009	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	breast: 12.0;skin: 5.4	esophagus: 1.8	Cell line enriched	14	hTCEpi: 233.8	Breast
PRSS51	NA	ENSG00000253649	Protease, serine 51	8	10482878-10547585	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	breast: 1.0;testis: 1.1	cerebral cortex: 0.5	Cell line enhanced	NA	U-2 OS: 1.4	Breast
PTHLH	HHM, PLP, PTHR, PTHRP	ENSG00000087494	Parathyroid hormone like hormone	12	27958084-27972705	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA035982	Approved	Approved	Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.82e-9 (unfavourable), Liver cancer:3.37e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	breast: 23.9	esophagus: 18.0	Group enriched	7	HaCaT: 256.2;HBEC3-KT: 257.7;U-251 MG: 64.3	Breast
SFRP1	FRP, FRP-1, SARP2	ENSG00000104332	Secreted frizzled related protein 1	8	41261958-41309497	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008116, HPA064870	Approved	NA	Approved	Nucleoli<br>Cytosol	Head and neck cancer:1.55e-4 (favourable), Urothelial cancer:3.12e-4 (unfavourable)	Mixed	Tissue enhanced	NA	breast: 357.2;cervix, uterine: 325.0	endometrium: 231.0	Cell line enhanced	NA	BJ hTERT+: 563.8;HBF TERT88: 268.7;RPTEC TERT1: 319.1;WM-115: 275.2	Breast
SHISA2	bA398O19.2, C13orf13, hShisa, PRO28631, TMEM46, WGAR9166	ENSG00000180730	Shisa family member 2	13	26044597-26051031	Predicted membrane proteins	Evidence at protein level	HPA049752, HPA050172	Uncertain	NA	Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Renal cancer:2.43e-4 (favourable), Lung cancer:3.30e-4 (favourable)	Mixed	Tissue enhanced	NA	breast: 22.3;thyroid gland: 48.3	epididymis: 13.1	Cell line enhanced	NA	LHCN-M2: 21.2;NTERA-2: 18.4;RH-30: 56.6;U-2197: 34.1	Breast
SLC28A3	CNT3	ENSG00000197506	Solute carrier family 28 member 3	9	84275457-84340683	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023311, HPA024729	Approved	NA	NA	NA	Breast cancer:3.37e-4 (favourable)	Mixed	Tissue enhanced	NA	breast: 10.7;gallbladder: 11.7;skin: 9.8	bone marrow: 6.2	Cell line enriched	8	HMC-1: 51.9	Breast
SPINK14	SPINK5L2	ENSG00000196800	Serine peptidase inhibitor, Kazal type 14 (putative)	5	148169733-148175398	Predicted secreted proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	breast: 1.1;rectum: 1.2	cervix, uterine: 0.7	Not detected	NA	NA	Breast
ST8SIA6	SIAT8F	ENSG00000148488	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6	10	17318383-17454330	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011635, HPA072708	Uncertain	NA	Uncertain	Endoplasmic reticulum	NA	Tissue enhanced	Tissue enhanced	NA	breast: 13.4;lung: 18.1	epididymis: 9.1	Cell line enriched	8	HMC-1: 442.5	Breast
STC2	STC-2	ENSG00000113739	Stanniocalcin 2	5	173314713-173329503	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045372	Uncertain	NA	Approved	Endoplasmic reticulum	Renal cancer:4.17e-8 (unfavourable), Head and neck cancer:1.76e-6 (unfavourable), Liver cancer:3.07e-5 (unfavourable), Breast cancer:7.40e-5 (favourable), Stomach cancer:7.57e-4 (unfavourable)	Tissue enriched	Tissue enhanced	NA	breast: 164.6	placenta: 33.2	Cell line enhanced	NA	LHCN-M2: 707.5;T-47d: 753.9;U-138 MG: 321.3	Breast
TFAP2A	AP-2, AP2TF, TFAP2	ENSG00000137203	Transcription factor AP-2 alpha	6	10393186-10419659	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000326, HPA028850, HPA056871	Enhanced	NA	Enhanced	Nucleoplasm	Lung cancer:1.09e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	breast: 40.0;placenta: 42.3;skin: 76.1	epididymis: 24.9	Cell line enhanced	NA	HDLM-2: 103.3	Breast
TRPS1	GC79, LGCR	ENSG00000104447	Transcriptional repressor GATA binding 1	8	115408496-115809673	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060380, HPA071767	Enhanced	NA	Supported	Nucleoplasm	Pancreatic cancer:3.16e-4 (unfavourable), Head and neck cancer:9.42e-4 (favourable)	Tissue enriched	Tissue enhanced	NA	breast: 75.9	testis: 22.6	Cell line enhanced	NA	SK-BR-3: 58.4;T-47d: 230.2	Breast
VEGFD	FIGF, VEGF-D	ENSG00000165197	Vascular endothelial growth factor D	X	15345591-15384376	Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA027342	Uncertain	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	breast: 25.0;lung: 59.3	adipose tissue: 13.2	Cell line enhanced	NA	ASC diff: 2.3;ASC TERT1: 2.0;HSkMC: 2.1	Breast
VTCN1	B7-H4, B7H4, B7S1, B7X, FLJ22418	ENSG00000134258	V-set domain containing T-cell activation inhibitor 1	1	117143587-117210960	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054200	Approved	NA	Approved	Plasma membrane<br>Cell Junctions<br>Focal adhesion sites	NA	Group enriched	Tissue enhanced	NA	breast: 129.4;fallopian tube: 51.3	cervix, uterine: 22.0	Group enriched	8	BEWO: 43.1;SK-BR-3: 182.1	Breast
XDH	XO, XOR	ENSG00000158125	Xanthine dehydrogenase	2	31334321-31414715	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062641, HPA069323	Supported	NA	Supported	Nucleus	Urothelial cancer:8.73e-6 (favourable)	Mixed	Tissue enhanced	NA	breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6	colon: 11.2	Cell line enhanced	NA	HBEC3-KT: 14.4;hTERT-HME1: 23.9	Breast
ZNF80	pT17	ENSG00000174255	Zinc finger protein 80	3	114234631-114237578	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA065484	Uncertain	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	breast: 6.4	lymph node: 2.7	Cell line enhanced	NA	MCF7: 1.2	Breast
INSL5	NA	ENSG00000172410	Insulin like 5	1	66797741-66801256	Predicted secreted proteins	Evidence at protein level	HPA030100, CAB033849	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	228	colon: 77.7;rectum: 141.9	cerebral cortex: 0.4	Not detected	NA	NA	Colon
AQP8	NA	ENSG00000103375	Aquaporin 8	16	25215731-25228940	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046259	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	129	colon: 321.2;pancreas: 269.5;rectum: 166.5	smooth muscle: 1.9	Not detected	NA	NA	Colon
MEP1A	PPHA	ENSG00000112818	Meprin A subunit alpha	6	46793390-46839782	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025163, HPA029416	Enhanced	NA	NA	NA	NA	Tissue enriched	Group enriched	42	colon: 117.8;duodenum: 282.2;rectum: 114.3;small intestine: 538.5	appendix: 6.2	Cell line enhanced	NA	BEWO: 1.2;CACO-2: 2.4;RPMI-8226: 1.0	Colon
PRAC1	C17orf92, PRAC	ENSG00000159182	Prostate cancer susceptibility candidate 1	17	48721719-48722522	Predicted intracellular proteins	Evidence at transcript level	HPA047871	Approved	NA	NA	NA	NA	Tissue enriched	Group enriched	38	colon: 102.9;prostate: 171.7;rectum: 220.8	urinary bladder: 4.3	Cell line enriched	32	PC-3: 343.9	Colon
ISX	RAXLX	ENSG00000175329	Intestine specific homeobox	22	35066136-35087387	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060328	Approved	NA	Supported	Nucleoplasm<br>Nuclear bodies	NA	Tissue enhanced	Group enriched	36	colon: 27.4;duodenum: 37.5;rectum: 28.2;small intestine: 29.7	smooth muscle: 0.8	Group enriched	12	CACO-2: 1.3;Hep G2: 3.1	Colon
CA1	Car1	ENSG00000133742	Carbonic anhydrase 1	8	85327608-85379014	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006558, CAB025790	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	30	bone marrow: 1216.6;colon: 1022.8;rectum: 2316.0	smooth muscle: 49.9	Cell line enriched	1560	HEL: 1145.7	Colon
TBX10	TBX13, TBX7	ENSG00000167800	T-box 10	11	67631303-67639560	Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA047881	Uncertain	NA	NA	NA	NA	Group enriched	Group enriched	27	colon: 8.8;duodenum: 5.8;rectum: 8.6;small intestine: 10.6	appendix: 0.3	Cell line enhanced	NA	NTERA-2: 5.3;RPMI-8226: 2.5;SK-BR-3: 9.3;U-2 OS: 2.7	Colon
BTNL3	BTN9.1, BTNLR	ENSG00000168903	Butyrophilin like 3	5	180988845-181006727	Predicted membrane proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Group enriched	Group enriched	25	colon: 24.5;duodenum: 115.1;rectum: 26.3;small intestine: 89.1	gallbladder: 2.5	Not detected	NA	NA	Colon
MUC12	MUC11	ENSG00000205277	Mucin 12, cell surface associated	7	100969623-101018949	Predicted membrane proteins	Evidence at protein level	HPA023835	Enhanced	NA	NA	NA	NA	Tissue enriched	Group enriched	24	colon: 49.6;rectum: 74.4	appendix: 2.5	Not detected	NA	NA	Colon
TMIGD1	TMIGD, UNQ9372	ENSG00000182271	Transmembrane and immunoglobulin domain containing 1	17	30316333-30334059	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021946	NA	NA	Approved	Mitochondria	NA	Tissue enhanced	Group enriched	23	colon: 81.8;rectum: 109.8;small intestine: 162.9	kidney: 5.1	Not detected	NA	NA	Colon
KRTAP13-2	KAP13-2	ENSG00000182816	Keratin associated protein 13-2	21	30371391-30372257	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Group enriched	20	colon: 1.9;rectum: 2.0	all non-specific tissues: 0.0	Not detected	NA	NA	Colon
MS4A12	FLJ20217, Ms4a10	ENSG00000071203	Membrane spanning 4-domains A12	11	60492778-60507430	Predicted membrane proteins	Evidence at protein level	HPA057657	Enhanced	NA	NA	NA	NA	Tissue enriched	Group enriched	19	colon: 235.5;rectum: 280.6	appendix: 13.2	Cell line enhanced	NA	RH-30: 1.1	Colon
NOX1	GP91-2, MOX1, NOH-1, NOH1	ENSG00000007952	NADPH oxidase 1	X	100843324-100874345	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	NA	NA	NA	NA	NA	Colorectal cancer:9.71e-4 (favourable)	Tissue enriched	Group enriched	17	colon: 58.7;rectum: 79.9	appendix: 3.9	Cell line enriched	19	CACO-2: 25.5	Colon
CD177	HNA2A, NB1, PRV1	ENSG00000204936	CD177 molecule	19	43353659-43363172	Predicted secreted proteins	Evidence at protein level	HPA041820, HPA046601	Enhanced	NA	NA	NA	Cervical cancer:3.66e-4 (favourable)	Tissue enhanced	Group enriched	16	bone marrow: 193.1;colon: 155.7;prostate: 105.4;rectum: 181.9	appendix: 9.7	Cell line enriched	23	RPMI-8226: 65.6	Colon
GUCA2A	GUCA2, STARA	ENSG00000197273	Guanylate cyclase activator 2A	1	42162691-42164718	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA018215	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	15	colon: 768.8;rectum: 859.2;small intestine: 1127.0	duodenum: 61.5	Cell line enhanced	NA	BEWO: 11.8;CACO-2: 8.2;NB-4: 2.0;U-2197: 2.5	Colon
PYY	PYY1	ENSG00000131096	Peptide YY	17	43952738-44004469	Predicted secreted proteins	Evidence at protein level	HPA010973, CAB016734	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	15	colon: 52.6;rectum: 39.2;small intestine: 27.4	duodenum: 2.5	Cell line enhanced	NA	HMC-1: 2.6	Colon
CHST5	FLJ22167, I-GLCNAC-6-ST	ENSG00000135702	Carbohydrate sulfotransferase 5	16	75528535-75535247	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043804	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	14	colon: 45.6;duodenum: 85.9;rectum: 59.7;small intestine: 83.5	stomach: 4.8	Mixed	NA	NA	Colon
GUCY2C	GUC2C, STAR	ENSG00000070019	Guanylate cyclase 2C	12	14612632-14696585	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037655, HPA073759	Uncertain	NA	Uncertain	Vesicles	Liver cancer:1.37e-5 (unfavourable)	Group enriched	Group enriched	13	colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2	appendix: 4.4	Cell line enhanced	NA	AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6	Colon
MYO1A	DFNA48, MYHL	ENSG00000166866	Myosin IA	12	57028517-57051198	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053490	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	13	colon: 67.8;duodenum: 333.2;rectum: 71.8;small intestine: 338.4	stomach: 16.1	Cell line enhanced	NA	BEWO: 1.9;CACO-2: 6.6;Hep G2: 3.7	Colon
NAT2	AAC2	ENSG00000156006	N-acetyltransferase 2	8	18391245-18401218	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043704	Uncertain	NA	NA	NA	Colorectal cancer:4.61e-5 (favourable)	Tissue enhanced	Group enriched	13	colon: 14.4;duodenum: 32.7;liver: 62.4;rectum: 14.0;small intestine: 27.1	smooth muscle: 2.3	Cell line enhanced	NA	RT4: 1.2;SCLC-21H: 2.5;SK-BR-3: 1.0	Colon
NXPE1	FAM55A, MGC34290	ENSG00000095110	Neurexophilin and PC-esterase domain family member 1	11	114521715-114559895	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049133	Enhanced	NA	NA	NA	NA	Tissue enriched	Group enriched	13	colon: 111.8;rectum: 165.9	appendix: 10.5	Not detected	NA	NA	Colon
SDHD	cybS, PGL, PGL1	ENSG00000255292	Succinate dehydrogenase complex subunit D	11	112086824-112193805	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA045727	Uncertain	NA	NA	NA	NA	Not detected	Tissue enriched	13	colon: 7.8	parathyroid gland: 0.5	Cell line enhanced	NA	A549: 23.8;CACO-2: 57.0;Hep G2: 19.6;hTEC/SVTERT24-B: 20.1;RT4: 30.5	Colon
LYPD8	NA	ENSG00000259823	LY6/PLAUR domain containing 8	1	248718649-248755739	Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enriched	Group enriched	12	colon: 216.6;rectum: 141.8	appendix: 14.4	Not detected	NA	NA	Colon
MOGAT2	DGAT2L5, FLJ22644, MGAT2	ENSG00000166391	Monoacylglycerol O-acyltransferase 2	11	75717819-75732958	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028834	Uncertain	NA	NA	NA	NA	Tissue enhanced	Group enriched	12	colon: 12.5;duodenum: 37.2;liver: 12.1;rectum: 12.5;small intestine: 43.6	appendix: 1.9	Group enriched	6	Hep G2: 2.7;RPMI-8226: 1.8	Colon
SLC39A5	NA	ENSG00000139540	Solute carrier family 39 member 5	12	56230049-56237846	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018423	NA	NA	Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.05e-4 (favourable)	Tissue enhanced	Group enriched	12	colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4	gallbladder: 10.0	Group enriched	62	CACO-2: 33.1;Hep G2: 39.7	Colon
AC011513.3	NA	ENSG00000267881	NA	19	41708612-41761282	Predicted secreted proteins	Evidence at transcript level	HPA011041	Approved	NA	NA	NA	NA	Tissue enhanced	Group enriched	11	colon: 41.2;esophagus: 10.3	appendix: 2.4	Not detected	NA	NA	Colon
C10orf99	AP-57, CSBF, FLJ21763, RLLV1833, UNQ1833	ENSG00000188373	Chromosome 10 open reading frame 99	10	84173738-84185294	Predicted secreted proteins	Evidence at protein level	HPA050920	Enhanced	NA	NA	NA	Renal cancer:1.20e-5 (unfavourable)	Mixed	Group enriched	11	colon: 239.2;esophagus: 185.4;rectum: 264.2	urinary bladder: 20.8	Cell line enriched	6	RT4: 37.2	Colon
PIGY	MGC14156	ENSG00000255072	Phosphatidylinositol glycan anchor biosynthesis class Y	4	88521573-88521789	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA059018	Uncertain	NA	NA	NA	NA	Not detected	Tissue enriched	11	colon: 1.0	all non-specific tissues: 0.0	Group enriched	10	AF22: 7.5;hTEC/SVTERT24-B: 10.7;MOLT-4: 13.8	Colon
CHP2	NA	ENSG00000166869	Calcineurin like EF-hand protein 2	16	23754627-23758951	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB072806	Approved	NA	NA	NA	NA	Tissue enhanced	Group enriched	10	colon: 119.1;duodenum: 252.0;rectum: 127.6;skin: 143.8;small intestine: 227.3	cervix, uterine: 17.1	Cell line enhanced	NA	hTERT-HME1: 4.5;NB-4: 4.6	Colon
GLRA2	GLR	ENSG00000101958	Glycine receptor alpha 2	X	14529298-14731812	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB070422	Approved	NA	NA	NA	NA	Mixed	Group enriched	10	cerebral cortex: 6.1;colon: 1.4;rectum: 4.3	testis: 0.3	Cell line enriched	41	AN3-CA: 16.1	Colon
HHLA2	B7-H5, B7H7, B7y	ENSG00000114455	HERV-H LTR-associating 2	3	108296490-108378285	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055478	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	10	colon: 87.7;duodenum: 87.1;gallbladder: 46.0;rectum: 90.5;small intestine: 143.9	stomach: 9.2	Cell line enhanced	NA	HDLM-2: 3.7;Karpas-707: 2.0	Colon
NR1I2	BXR, ONR1, PAR2, PXR, SXR	ENSG00000144852	Nuclear receptor subfamily 1 group I member 2	3	119780484-119818485	FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029309, HPA055121, HPA073926	NA	NA	Enhanced	Nucleoplasm	NA	Group enriched	Group enriched	10	colon: 10.3;duodenum: 27.2;gallbladder: 6.4;liver: 20.0;rectum: 10.7;small intestine: 30.0	stomach: 1.7	Group enriched	7	Hep G2: 9.8;RH-30: 3.3	Colon
ATOH1	bHLHa14, HATH1, MATH-1, Math1	ENSG00000172238	Atonal bHLH transcription factor 1	4	93828753-93830964	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	NA	NA	NA	NA	NA	Colorectal cancer:3.26e-5 (favourable)	Tissue enhanced	Group enriched	9	colon: 17.6;duodenum: 11.1;rectum: 19.7;small intestine: 22.4	appendix: 1.9	Not detected	NA	NA	Colon
CDHR5	FLJ20219, MU-PCDH, MUCDHL, MUPCDH	ENSG00000099834	Cadherin related family member 5	11	616565-626078	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009081, HPA009173, CAB025004	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	9	colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3	gallbladder: 5.3	Cell line enhanced	NA	CACO-2: 2.1	Colon
CDX1	NA	ENSG00000113722	Caudal type homeobox 1	5	150166795-150184558	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055196	Enhanced	NA	NA	NA	NA	Tissue enhanced	Group enriched	9	colon: 129.9;duodenum: 64.5;rectum: 134.7;small intestine: 104.9	appendix: 12.1	Cell line enhanced	NA	BJ hTERT+: 5.4;SH-SY5Y: 1.3	Colon
LRRC19	FLJ21302	ENSG00000184434	Leucine rich repeat containing 19	9	26993136-27005693	Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	Renal cancer:7.08e-8 (favourable)	Group enriched	Group enriched	9	colon: 35.9;duodenum: 23.7;gallbladder: 9.4;kidney: 45.1;rectum: 35.3;small intestine: 34.7	appendix: 3.5	Not detected	NA	NA	Colon
NXPE4	C11orf33, FAM55D, FLJ20127	ENSG00000137634	Neurexophilin and PC-esterase domain family member 4	11	114570591-114595762	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042801	Approved	NA	NA	NA	NA	Tissue enriched	Group enriched	9	colon: 139.6;rectum: 158.4;salivary gland: 38.2	appendix: 11.9	Not detected	NA	NA	Colon
REG4	GISP, REG-IV, RELP	ENSG00000134193	Regenerating family member 4	1	119794018-119811660	Predicted secreted proteins	Evidence at protein level	CAB025867, HPA046555	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	9	colon: 215.7;duodenum: 239.5;rectum: 299.4;small intestine: 664.5	appendix: 39.6	Group enriched	24	PC-3: 85.3;RT4: 20.5	Colon
TMEM236	bA162I21.2, bA16O1.2, FAM23A, FAM23B	ENSG00000148483	Transmembrane protein 236	10	17752252-17800868	Predicted membrane proteins	Evidence at protein level	HPA045096	Enhanced	NA	NA	NA	NA	Tissue enhanced	Group enriched	9	colon: 14.4;duodenum: 22.1;rectum: 15.5;small intestine: 37.7	appendix: 2.3	Cell line enriched	9	MOLT-4: 8.4	Colon
CDH17	cadherin, HPT-1	ENSG00000079112	Cadherin 17	8	94127171-94217303	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023614, HPA023616, CAB025143, HPA026556	Enhanced	NA	Supported	Cell Junctions	NA	Group enriched	Group enriched	8	colon: 256.9;duodenum: 314.3;rectum: 267.3;small intestine: 294.3	appendix: 37.5	Group enriched	6	CACO-2: 81.5;U-266/70: 121.0	Colon
CLCA1	CaCC, CLCRG1	ENSG00000016490	Chloride channel accessory 1	1	86468368-86500289	Predicted secreted proteins, Transporters	Evidence at protein level	HPA052787, HPA059301	Enhanced	NA	NA	NA	Colorectal cancer:2.98e-4 (favourable)	Group enriched	Group enriched	8	colon: 699.6;duodenum: 882.2;rectum: 1126.3;small intestine: 1522.4	appendix: 133.7	Cell line enhanced	NA	BEWO: 1.9;NB-4: 1.5;RPMI-8226: 1.8;SH-SY5Y: 1.9;U-2197: 1.3	Colon
CLRN3	MGC32871, TMEM12, USH3AL1	ENSG00000180745	Clarin 3	10	127877841-127892947	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014482	Approved	NA	NA	NA	Stomach cancer:8.98e-4 (favourable)	Group enriched	Group enriched	8	colon: 69.9;duodenum: 73.3;gallbladder: 23.6;kidney: 44.3;liver: 40.4;rectum: 76.3;small intestine: 97.5	appendix: 7.2	Cell line enriched	6	CACO-2: 1.9	Colon
DHRS11	MGC4172, SDR24C1	ENSG00000278535	Dehydrogenase/reductase 11	17	36591798-36600806	Predicted intracellular proteins	Evidence at protein level	HPA041226, HPA048236, HPA053623	Enhanced	NA	Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.24e-4 (favourable)	Expressed in all	Group enriched	8	colon: 44.6;duodenum: 149.5;rectum: 47.1;small intestine: 133.6	testis: 11.8	Mixed	NA	NA	Colon
GAL3ST2	GP3ST	ENSG00000154252	Galactose-3-O-sulfotransferase 2	2	241776825-241804208	Predicted secreted proteins	Evidence at protein level	HPA071809	Enhanced	NA	NA	NA	NA	Group enriched	Group enriched	8	colon: 9.3;rectum: 4.0	appendix,fallopian tube: 0.8	Cell line enhanced	NA	Hep G2: 1.4	Colon
GPA33	A33	ENSG00000143167	Glycoprotein A33	1	167052836-167166479	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018858, CAB025943	Enhanced	NA	NA	NA	NA	Tissue enriched	Group enriched	8	colon: 183.6;duodenum: 130.8;rectum: 188.7;small intestine: 131.3	appendix: 19.0	Cell line enhanced	NA	NTERA-2: 1.0	Colon
HOXD13	HOX4I, SPD	ENSG00000128714	Homeobox D13	2	176092891-176095938	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064064	NA	NA	Supported	Nucleus	Colorectal cancer:6.95e-5 (unfavourable)	Mixed	Group enriched	8	cervix, uterine: 7.9;colon: 4.9;prostate: 16.9;rectum: 9.5;seminal vesicle: 24.5	urinary bladder: 1.5	Cell line enhanced	NA	HAP1: 20.6;HEK93: 52.3;HL-60: 52.4;NB-4: 24.7;SCLC-21H: 19.3	Colon
CEACAM7	CEA, CGM2	ENSG00000007306	Carcinoembryonic antigen related cell adhesion molecule 7	19	41673307-41706976	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069621	Supported	NA	NA	NA	NA	Tissue enhanced	Group enriched	7	colon: 583.2;rectum: 691.9	appendix: 91.6	Not detected	NA	NA	Colon
EPS8L3	FLJ21522, MGC16817	ENSG00000198758	EPS8 like 3	1	109750080-109764027	Predicted intracellular proteins	Evidence at protein level	HPA030998	Approved	NA	Approved	Vesicles	Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable)	Group enriched	Group enriched	7	colon: 75.0;duodenum: 152.1;gallbladder: 59.8;rectum: 86.1;small intestine: 167.1;stomach: 53.4	appendix: 15.1	Group enriched	12	CACO-2: 13.3;CAPAN-2: 13.3;EFO-21: 5.8;Hep G2: 25.0	Colon
ERN2	IRE1b	ENSG00000134398	Endoplasmic reticulum to nucleus signaling 2	16	23690326-23713500	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016558	Uncertain	NA	NA	NA	NA	Mixed	Group enriched	7	cervix, uterine: 27.6;colon: 27.5;duodenum: 12.3;gallbladder: 25.1;rectum: 23.2;small intestine: 9.9;stomach: 49.1	appendix: 3.8	Cell line enriched	8	CAPAN-2: 5.9	Colon
FABP1	L-FABP	ENSG00000163586	Fatty acid binding protein 1	2	88122982-88128116	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002305, HPA028275	Enhanced	NA	Approved	Nucleoplasm<br>Cytosol	NA	Group enriched	Group enriched	7	colon: 4552.0;duodenum: 4123.5;liver: 5672.8;rectum: 3081.5;small intestine: 4506.9	kidney: 602.3	Group enriched	6	CACO-2: 84.1;Hep G2: 221.3	Colon
FSIP1	FLJ35989	ENSG00000150667	Fibrous sheath interacting protein 1	15	39600031-39782830	Predicted intracellular proteins	Evidence at protein level	HPA041002	Uncertain	NA	Uncertain	Nucleoplasm	NA	Tissue enriched	Group enriched	7	colon: 11.2;rectum: 18.4;testis: 13.6	breast: 2.2	Mixed	NA	NA	Colon
GALNT8	GALNAC-T8	ENSG00000130035	Polypeptide N-acetylgalactosaminyltransferase 8	12	4720341-4851927	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012638, HPA014418, HPA073461	Approved	NA	Approved	Vesicles	NA	Tissue enhanced	Group enriched	7	cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5	appendix: 3.2	Cell line enhanced	NA	Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3	Colon
LRRC26	bA350O14.10	ENSG00000184709	Leucine rich repeat containing 26	9	137168758-137170051	Predicted membrane proteins	Evidence at protein level	HPA056312	Approved	NA	Supported	Nucleoli fibrillar center<br>Plasma membrane	Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable)	Tissue enriched	Group enriched	7	colon: 10.2;prostate: 35.5;salivary gland: 26.5	small intestine: 3.5	Group enriched	10	REH: 18.9;RPMI-8226: 87.4	Colon
PHGR1	NA	ENSG00000233041	Proline, histidine and glycine rich 1	15	40351033-40356434	Predicted intracellular proteins	Evidence at protein level	HPA068787	Enhanced	NA	Approved	Vesicles	Breast cancer:2.05e-4 (favourable)	Group enriched	Group enriched	7	colon: 1448.4;duodenum: 892.1;rectum: 399.5;small intestine: 1777.5	stomach: 166.8	Cell line enhanced	NA	BEWO: 12.3;HaCaT: 16.0;SCLC-21H: 72.5	Colon
PPP1R14D	CPI17-like, FLJ20251, GBPI-1, MGC119014, MGC119016	ENSG00000166143	Protein phosphatase 1 regulatory inhibitor subunit 14D	15	40815445-40828709	Predicted intracellular proteins	Evidence at protein level	HPA041846	Uncertain	NA	NA	NA	Renal cancer:3.07e-4 (unfavourable)	Tissue enhanced	Group enriched	7	colon: 105.5;duodenum: 111.1;gallbladder: 24.2;rectum: 100.0;small intestine: 89.8	appendix: 12.4	Cell line enhanced	NA	RPMI-8226: 2.1;RT4: 1.5;U-266/84: 1.4	Colon
SH2D7	LOC646892	ENSG00000183476	SH2 domain containing 7	15	78077808-78104909	Predicted intracellular proteins	Evidence at transcript level	HPA051320	Approved	NA	NA	NA	NA	Mixed	Group enriched	7	colon: 1.6;duodenum: 2.1;small intestine: 1.9;testis: 5.7	cerebral cortex: 0.4	Cell line enhanced	NA	SH-SY5Y: 1.4	Colon
VIL1	D2S1471, VIL	ENSG00000127831	Villin 1	2	218419092-218453295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002452, HPA006884, HPA006885	Enhanced	NA	Enhanced	Plasma membrane	NA	Tissue enhanced	Group enriched	7	colon: 173.7;duodenum: 398.5;rectum: 199.6;small intestine: 480.0	gallbladder: 44.7	Group enriched	91	CACO-2: 628.4;Hep G2: 245.1	Colon
AMN	amnionless	ENSG00000166126	Amnion associated transmembrane protein	14	102922656-102933596	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000817	Approved	NA	NA	NA	Renal cancer:9.62e-5 (favourable)	Mixed	Group enriched	6	colon: 20.0;duodenum: 34.2;kidney: 29.0;small intestine: 70.6	liver: 6.7	Cell line enhanced	NA	CACO-2: 6.8;Hep G2: 5.6;U-698: 3.0	Colon
BTNL8	BTN9.2, FLJ21458	ENSG00000113303	Butyrophilin like 8	5	180899077-180950906	Predicted membrane proteins	Evidence at protein level	HPA039738	Approved	NA	NA	NA	NA	Group enriched	Group enriched	6	colon: 26.1;duodenum: 117.4;rectum: 27.7;small intestine: 94.2	gallbladder: 10.4	Cell line enriched	26	CACO-2: 31.4	Colon
CASP5	ICE(rel)III	ENSG00000137757	Caspase 5	11	104994235-105023168	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040937	Uncertain	NA	NA	NA	NA	Group enriched	Group enriched	6	appendix: 20.2;colon: 15.9;duodenum: 10.1;rectum: 14.5;small intestine: 18.9	smooth muscle: 2.7	Cell line enriched	8	HHSteC: 3.1	Colon
CDX2	CDX3	ENSG00000165556	Caudal type homeobox 2	13	27962137-27971139	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002221, HPA045669, HPA049580	Enhanced	NA	Supported	Nucleoplasm	NA	Tissue enriched	Group enriched	6	colon: 30.8;duodenum: 22.3;rectum: 24.9;small intestine: 30.2	appendix: 4.7	Cell line enhanced	NA	CACO-2: 9.4;CAPAN-2: 3.3;HEK93: 5.6	Colon
CEACAM6	CD66c, NCA	ENSG00000086548	Carcinoembryonic antigen related cell adhesion molecule 6	19	41750977-41772208	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB008370, HPA011041	Enhanced	NA	NA	NA	NA	Mixed	Group enriched	6	bone marrow: 110.7;colon: 180.6;esophagus: 173.5;gallbladder: 189.0;lung: 405.6;rectum: 233.8	appendix: 37.6	Cell line enriched	9	A549: 140.1	Colon
CLCA4	CaCC2	ENSG00000016602	Chloride channel accessory 4	1	86547078-86580754	Predicted membrane proteins	Evidence at protein level	HPA017045	Uncertain	NA	NA	NA	Colorectal cancer:7.47e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)	Tissue enhanced	Group enriched	6	colon: 249.5;esophagus: 365.5;rectum: 158.4	urinary bladder: 41.0	Cell line enriched	1215	RT4: 342.2	Colon
EFNA2	ELF-1, EPLG6, LERK6	ENSG00000099617	Ephrin A2	19	1286154-1300237	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005178, HPA067567	Uncertain	NA	Approved	Mitochondria<br>Cytosol	NA	Tissue enhanced	Group enriched	6	colon: 7.0;duodenum: 7.9;small intestine: 10.6	rectum: 1.5	Cell line enhanced	NA	Hep G2: 6.6;NTERA-2: 5.4;REH: 6.8;SH-SY5Y: 17.8;U-2 OS: 5.8	Colon
HAVCR1	CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1	ENSG00000113249	Hepatitis A virus cellular receptor 1	5	157029413-157059119	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007173, CAB075697	Approved	NA	Approved	Vesicles	Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)	Tissue enriched	Group enriched	6	colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7	gallbladder: 0.8	Group enriched	5	A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8	Colon
HNF4A	HNF4, MODY, MODY1, NR2A1, TCF14	ENSG00000101076	Hepatocyte nuclear factor 4 alpha	20	44355700-44434596	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004712, CAB019417	Enhanced	NA	Supported	Nucleoplasm	NA	Tissue enhanced	Group enriched	6	colon: 58.0;duodenum: 103.0;kidney: 44.7;liver: 51.0;rectum: 47.8;small intestine: 90.9;stomach: 21.9	gallbladder: 9.2	Group enriched	8	CACO-2: 126.0;Hep G2: 77.0	Colon
IHH	BDA1, HHG2	ENSG00000163501	Indian hedgehog	2	219054420-219060467	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Endometrial cancer:3.67e-6 (favourable)	Tissue enhanced	Group enriched	6	cervix, uterine: 8.9;colon: 21.0;duodenum: 14.9;endometrium: 31.4;rectum: 16.7;small intestine: 16.5;stomach: 15.3	prostate: 3.2	Cell line enriched	11	CACO-2: 16.8	Colon
LINC01207	NA	ENSG00000248771	Long intergenic non-protein coding RNA 1207	4	164754064-164803795	Predicted secreted proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Group enriched	6	cervix, uterine: 4.4;colon: 6.3;duodenum: 10.5;gallbladder: 6.2;prostate: 9.0;rectum: 7.8;small intestine: 12.4	appendix: 1.4	Not detected	NA	NA	Colon
MISP	C19orf21, Caprice, DKFZp686H18209, MISP1	ENSG00000099812	Mitotic spindle positioning	19	751126-764318	Predicted intracellular proteins	Evidence at protein level	HPA049511, HPA062232	Enhanced	NA	Enhanced	Plasma membrane<br>Focal adhesion sites	NA	Tissue enhanced	Group enriched	6	colon: 94.7;duodenum: 173.3;rectum: 52.6;small intestine: 217.1	stomach: 21.6	Cell line enhanced	NA	A549: 110.0;HaCaT: 79.4;hTCEpi: 59.7;SK-BR-3: 101.1	Colon
MOGAT3	DC7, DGAT2L2, MGAT3	ENSG00000106384	Monoacylglycerol O-acyltransferase 3	7	101195007-101201021	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011940	Uncertain	NA	Approved	Centrosome	NA	Tissue enhanced	Group enriched	6	colon: 11.3;duodenum: 30.4;rectum: 11.9;small intestine: 33.6	liver: 3.4	Cell line enhanced	NA	CACO-2: 2.9;Hep G2: 8.1	Colon
MUC13	DRCC1	ENSG00000173702	Mucin 13, cell surface associated	3	124905442-124953819	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045163	Enhanced	NA	NA	NA	Renal cancer:9.73e-5 (unfavourable)	Tissue enhanced	Group enriched	6	colon: 301.8;duodenum: 614.7;rectum: 330.1;small intestine: 555.7	appendix: 79.5	Cell line enhanced	NA	A549: 6.6;CACO-2: 5.3;CAPAN-2: 11.9;Karpas-707: 5.6	Colon
NEU4	NA	ENSG00000204099	Neuraminidase 4	2	241808825-241817413	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037394, HPA037395	Uncertain	NA	NA	NA	NA	Group enriched	Group enriched	6	bone marrow: 2.4;cerebral cortex: 6.3;colon: 8.3;duodenum: 5.6;liver: 4.1;rectum: 3.7;small intestine: 5.3	fallopian tube,gallbladder: 0.7	Group enriched	20	Hep G2: 26.3;HMC-1: 45.5	Colon
SLC17A4	KIAA2138	ENSG00000146039	Solute carrier family 17 member 4	6	25754699-25781191	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA055564	Approved	NA	NA	NA	NA	Group enriched	Group enriched	6	colon: 20.4;duodenum: 28.6;gallbladder: 25.4;liver: 22.3;rectum: 28.9;small intestine: 35.0	pancreas: 4.2	Cell line enriched	5	RPTEC TERT1: 1.1	Colon
SPINK4	MGC133107, PEC-60	ENSG00000122711	Serine peptidase inhibitor, Kazal type 4	9	33218365-33248567	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007286	Enhanced	NA	Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Colorectal cancer:8.85e-5 (favourable)	Group enriched	Group enriched	6	colon: 631.8;duodenum: 266.4;rectum: 1071.3;small intestine: 734.5	appendix: 107.1	Cell line enriched	8	HMC-1: 152.9	Colon
TPH1	TPH, TPRH	ENSG00000129167	Tryptophan hydroxylase 1	11	18017564-18042426	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010767, HPA022483	Enhanced	NA	Uncertain	Cytosol	NA	Mixed	Group enriched	6	colon: 8.8;duodenum: 10.2;rectum: 21.0;small intestine: 12.6;stomach: 15.5	prostate: 2.4	Mixed	NA	NA	Colon
TRIM31	C6orf13, HCG1, HCGI, RNF	ENSG00000204616	Tripartite motif containing 31	6	30102897-30113106	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046400	Uncertain	NA	NA	NA	NA	Group enriched	Group enriched	6	colon: 10.0;small intestine: 2.3;stomach: 2.1;urinary bladder: 2.7	duodenum: 0.7	Cell line enriched	527	RT4: 232.7	Colon
URAD	PRHOXNB	ENSG00000183463	Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase	13	27977714-27988654	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA038972	Uncertain	NA	NA	NA	NA	Tissue enriched	Group enriched	6	colon: 12.6;duodenum: 8.3;small intestine: 17.9	appendix: 2.3	Group enriched	12	BEWO: 2.6;CACO-2: 2.1	Colon
ZG16	hZG16, JCLN, JCLN1, ZG16A	ENSG00000174992	Zymogen granule protein 16	16	29778240-29782973	Predicted secreted proteins	Evidence at protein level	HPA052066, HPA052512	Enhanced	NA	NA	NA	NA	Tissue enriched	Group enriched	6	colon: 363.4;rectum: 502.4;small intestine: 121.4	duodenum: 57.7	Cell line enhanced	NA	SK-BR-3: 1.7	Colon
B3GALT5	B3GalT-V, B3T5, beta3Gal-T5, GLCT5	ENSG00000183778	Beta-1,3-galactosyltransferase 5	21	39556442-39673137	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054092, HPA054684	Approved	NA	NA	NA	Endometrial cancer:6.36e-4 (favourable)	Mixed	Group enriched	5	colon: 22.7;duodenum: 27.5;gallbladder: 8.6;rectum: 40.5;small intestine: 37.2	stomach: 5.0	Group enriched	5	CAPAN-2: 20.6;NTERA-2: 6.3;RPTEC TERT1: 20.7;SCLC-21H: 5.4	Colon
FOXA3	HNF3G	ENSG00000170608	Forkhead box A3	19	45863989-45873797	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB015154, HPA054034	Uncertain	NA	Approved	Nucleoplasm	NA	Mixed	Group enriched	5	colon: 16.7;duodenum: 10.3;liver: 32.5;pancreas: 9.8;rectum: 17.9;small intestine: 13.9;stomach: 33.8	gallbladder: 3.6	Cell line enhanced	NA	CACO-2: 8.4;HDLM-2: 11.2;Hep G2: 18.9;K-562: 20.1;NTERA-2: 10.8	Colon
IL22RA1	CRF2-9, IL22R	ENSG00000142677	Interleukin 22 receptor subunit alpha 1	1	24119771-24143121	Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Mixed	Group enriched	5	colon: 11.3;duodenum: 20.2;esophagus: 10.1;pancreas: 26.1;rectum: 10.9;skin: 38.7;small intestine: 31.3	gallbladder: 4.0	Cell line enhanced	NA	CACO-2: 9.3;HaCaT: 4.5;Hep G2: 5.5	Colon
LRRC31	FLJ23259	ENSG00000114248	Leucine rich repeat containing 31	3	169839179-169869930	Predicted intracellular proteins	Evidence at protein level	HPA037548	Uncertain	NA	NA	NA	NA	Mixed	Group enriched	5	colon: 18.2;duodenum: 8.8;rectum: 24.3;small intestine: 11.0;stomach: 9.8	liver: 2.8	Cell line enhanced	NA	EFO-21: 1.8;HAP1: 1.4;RPTEC TERT1: 1.6	Colon
NOS2	HEP-NOS, iNOS, NOS, NOS2A	ENSG00000007171	Nitric oxide synthase 2	17	27756766-27800499	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002014	Approved	NA	NA	NA	NA	Tissue enhanced	Group enriched	5	appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5	smooth muscle: 2.5	Group enriched	8	CACO-2: 13.0;SCLC-21H: 14.7	Colon
SATB2	FLJ21474, KIAA1034	ENSG00000119042	SATB homeobox 2	2	199269500-199471266	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001042, CAB023669, HPA029543, CAB062562, CAB067751, CAB068229, CAB068230, CAB068231	Enhanced	NA	Supported	Nucleoplasm	Renal cancer:5.37e-8 (favourable)	Tissue enhanced	Group enriched	5	cerebral cortex: 22.7;colon: 34.1;rectum: 43.2	small intestine: 6.3	Mixed	NA	NA	Colon
SULT1B1	ST1B2	ENSG00000173597	Sulfotransferase family 1B member 1	4	69721162-69787961	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002107	Enhanced	NA	Approved	Nucleoplasm<br>Golgi apparatus	NA	Group enriched	Group enriched	5	colon: 68.9;duodenum: 99.0;rectum: 67.1;small intestine: 103.7;stomach: 41.6	appendix: 13.8	Group enriched	6	HUVEC TERT2: 92.0;TIME: 29.6;U-2197: 29.2	Colon
TRPM5	LTRPC5, MTR1	ENSG00000070985	Transient receptor potential cation channel subfamily M member 5	11	2404515-2423045	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA042115, HPA043315	Uncertain	NA	NA	NA	NA	Tissue enhanced	Group enriched	5	colon: 1.0;duodenum: 2.9;epididymis: 2.2;seminal vesicle: 2.5;small intestine: 2.9	testis,thyroid gland: 0.4	Not detected	NA	NA	Colon
VIP	NA	ENSG00000146469	Vasoactive intestinal peptide	6	152750798-152759765	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017324, CAB018649, HPA072701	Supported	NA	Approved	Endoplasmic reticulum	NA	Group enriched	Group enriched	5	appendix: 209.4;colon: 71.4;rectum: 68.3;small intestine: 52.7;smooth muscle: 58.1	duodenum: 16.8	Cell line enhanced	NA	SH-SY5Y: 2.8;TIME: 1.6	Colon
AC009133.22	NA	ENSG00000277669	NA	16	29663279-29695144	Predicted secreted proteins	Evidence at protein level	HPA011887	Uncertain	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	colon: 2.6;duodenum: 1.8;spleen: 1.0	lung: 0.4	Cell line enhanced	NA	BEWO: 44.0;EFO-21: 114.1;SH-SY5Y: 19.3	Colon
ADAMDEC1	M12.219	ENSG00000134028	ADAM like decysin 1	8	24384285-24406013	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	colon: 210.9;rectum: 339.7;small intestine: 476.3	duodenum: 189.1	Group enriched	7	U-266/70: 8.1;U-266/84: 1.9	Colon
AIFM3	AIFL, FLJ30473	ENSG00000183773	Apoptosis inducing factor, mitochondria associated 3	22	20965108-20981360	Predicted intracellular proteins	Evidence at protein level	HPA001271	NA	NA	Enhanced	Mitochondria	Urothelial cancer:7.13e-5 (favourable)	Tissue enhanced	Tissue enhanced	NA	cerebral cortex: 18.5;colon: 18.7	rectum: 9.0	Cell line enhanced	NA	Hep G2: 5.1;HMC-1: 9.5;T-47d: 5.0;THP-1: 5.1	Colon
ATP10B	ATPVB, FLJ21477, KIAA0715	ENSG00000118322	ATPase phospholipid transporting 10B (putative)	5	160563120-160852214	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034574	Uncertain	NA	NA	NA	NA	Group enriched	Tissue enhanced	NA	colon: 36.0;rectum: 40.3	gallbladder: 21.4	Cell line enriched	23	WM-115: 13.6	Colon
B3GALT1	beta3Gal-T1	ENSG00000172318	Beta-1,3-galactosyltransferase 1	2	167868948-167874041	Enzymes, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	cerebral cortex: 5.2;colon: 3.7;rectum: 4.0	skeletal muscle: 1.8	Cell line enriched	7	AN3-CA: 33.1	Colon
B3GNT6	B3Gn-T6	ENSG00000198488	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6	11	77034398-77041973	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA012158, HPA039805	Enhanced	Approved	NA	NA	Colorectal cancer:2.31e-4 (favourable)	Group enriched	Tissue enhanced	NA	colon: 21.7;rectum: 18.2;stomach: 23.5	small intestine: 7.9	Not detected	NA	NA	Colon
B4GALNT2	Cad, GALGT2, Sda	ENSG00000167080	Beta-1,4-N-acetyl-galactosaminyltransferase 2	17	49132460-49176840	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015721	Approved	NA	NA	NA	Renal cancer:1.29e-5 (favourable)	Mixed	Tissue enhanced	NA	colon: 33.3	rectum: 14.9	Mixed	NA	NA	Colon
BCL2L15	Bfk, C1orf178, FLJ22588	ENSG00000188761	BCL2 like 15	1	113878168-113887547	Predicted intracellular proteins	Evidence at protein level	HPA029732, HPA029733	Enhanced	NA	NA	NA	Endometrial cancer:5.63e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	colon: 47.4;duodenum: 66.5;rectum: 52.2;small intestine: 64.3	stomach: 24.0	Cell line enhanced	NA	CAPAN-2: 22.4;EFO-21: 8.1;RPTEC TERT1: 5.6	Colon
BEST2	FLJ20132, VMD2L1	ENSG00000039987	Bestrophin 2	19	12751702-12758458	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA046229	Approved	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 15.4;rectum: 14.8	tonsil: 4.5	Mixed	NA	NA	Colon
BEST4	VMD2L2	ENSG00000142959	Bestrophin 4	1	44783585-44787705	Predicted membrane proteins	Evidence at protein level	HPA058564	Uncertain	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	colon: 26.2;rectum: 21.3	duodenum: 11.3	Cell line enhanced	NA	Hep G2: 2.1	Colon
C15orf48	NMES1	ENSG00000166920	Chromosome 15 open reading frame 48	15	45430529-45448761	Predicted intracellular proteins	Evidence at protein level	HPA012943	Enhanced	NA	NA	NA	NA	Expressed in all	Tissue enhanced	NA	colon: 716.6;rectum: 832.9	small intestine: 330.3	Cell line enhanced	NA	A-431: 52.4;CAPAN-2: 96.3	Colon
C2orf72	LOC257407	ENSG00000204128	Chromosome 2 open reading frame 72	2	231037490-231049719	Predicted intracellular proteins	Evidence at protein level	HPA044962	Uncertain	NA	Approved	Nucleus<br>Plasma membrane	Renal cancer:4.74e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	cerebral cortex: 2.8;colon: 2.9;liver: 4.7	stomach: 1.3	Cell line enhanced	NA	BEWO: 8.2;CACO-2: 1.7;EFO-21: 2.9	Colon
CA2	CA-II, CAII, Car2	ENSG00000104267	Carbonic anhydrase 2	8	85463852-85481493	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001550, CAB010102	Enhanced	NA	NA	NA	Renal cancer:5.57e-6 (favourable)	Expressed in all	Tissue enhanced	NA	colon: 604.8;rectum: 627.5;stomach: 918.8	kidney: 308.3	Group enriched	11	HaCaT: 204.1;HEK93: 884.1;THP-1: 278.7	Colon
CA4	CAIV, Car4, RP17	ENSG00000167434	Carbonic anhydrase 4	17	60149936-60170899	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011089, HPA017258	Enhanced	NA	Supported	Vesicles	NA	Mixed	Tissue enhanced	NA	colon: 253.5;rectum: 180.9	adipose tissue: 88.7	Not detected	NA	NA	Colon
CA7	NA	ENSG00000168748	Carbonic anhydrase 7	16	66844379-66854153	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047237	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 54.6;rectum: 49.8	small intestine: 10.7	Cell line enhanced	NA	REH: 1.0;SCLC-21H: 1.0;THP-1: 1.2	Colon
CDC42EP5	Borg3, CEP5	ENSG00000167617	CDC42 effector protein 5	19	54465026-54473264	Predicted intracellular proteins	Evidence at protein level	HPA043449	Approved	NA	NA	NA	Renal cancer:2.79e-5 (unfavourable), Urothelial cancer:1.36e-4 (favourable)	Expressed in all	Tissue enhanced	NA	colon: 3.1;prostate: 2.4	adipose tissue: 0.9	Not detected	NA	NA	Colon
CEACAM1	BGP, BGP1, CD66a	ENSG00000079385	Carcinoembryonic antigen related cell adhesion molecule 1	19	42507304-42561234	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002146, HPA011041	Enhanced	NA	NA	NA	Endometrial cancer:6.32e-7 (favourable)	Mixed	Tissue enhanced	NA	colon: 202.3;rectum: 130.6	esophagus: 46.5	Cell line enhanced	NA	CAPAN-2: 25.2;Hep G2: 56.7;RT4: 43.1;SK-MEL-30: 47.4	Colon
CEACAM5	CD66e, CEA	ENSG00000105388	Carcinoembryonic antigen related cell adhesion molecule 5	19	41708585-41729798	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000021, CAB000022, HPA011041, HPA019758	Enhanced	NA	Supported	Plasma membrane	NA	Tissue enhanced	Tissue enhanced	NA	colon: 1012.7;rectum: 1086.0	appendix: 257.7	Cell line enriched	6	HaCaT: 11.8	Colon
CES3	ES31, FLJ21736	ENSG00000172828	Carboxylesterase 3	16	66961237-66975148	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041008, HPA041307	Approved	NA	Approved	Nuclear membrane<br>Endoplasmic reticulum	Liver cancer:7.26e-5 (favourable)	Mixed	Tissue enhanced	NA	colon: 37.2;duodenum: 30.5;rectum: 34.1	small intestine: 26.6	Cell line enhanced	NA	AN3-CA: 7.1	Colon
CH17-360D5.1	NA	ENSG00000264717	NA	10	47918739-47923524	Predicted membrane proteins	Evidence at transcript level	HPA027863	Uncertain	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	colon: 3.0;rectum: 2.4	skin: 2.0	Cell line enriched	12	A549: 17.8	Colon
CKMT1B	CKMT, CKMT1, UMTCK	ENSG00000237289	Creatine kinase, mitochondrial 1B	15	43593054-43604901	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA043491	Uncertain	NA	NA	NA	Endometrial cancer:2.55e-5 (unfavourable)	Mixed	Tissue enhanced	NA	colon: 78.0;rectum: 68.4	duodenum: 63.0	Cell line enhanced	NA	HaCaT: 120.7;SCLC-21H: 60.9;SK-BR-3: 124.3;T-47d: 91.0	Colon
CLDN23	CLDNL	ENSG00000253958	Claudin 23	8	8701938-8704106	Predicted membrane proteins, Transporters	Evidence at protein level	HPA070578	NA	NA	Uncertain	Nucleus<br>Plasma membrane	Renal cancer:9.65e-8 (favourable), Colorectal cancer:3.46e-4 (favourable)	Expressed in all	Tissue enhanced	NA	colon: 23.7;stomach: 24.5	small intestine: 16.5	Cell line enhanced	NA	BEWO: 7.4	Colon
CLDN3	C7orf1, CPE-R2, CPETR2, HRVP1, RVP1	ENSG00000165215	Claudin 3	7	73768997-73770270	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002702, HPA014361	Supported	NA	Supported	Cell Junctions	Renal cancer:3.39e-5 (favourable)	Mixed	Tissue enhanced	NA	colon: 87.7;small intestine: 119.5	duodenum: 55.0	Cell line enhanced	NA	MCF7: 175.3;PC-3: 44.1;SCLC-21H: 68.2;T-47d: 98.9	Colon
CTC-273B12.7	NA	ENSG00000268465	NA	19	48465837-48472431	Predicted intracellular proteins	Evidence at transcript level	HPA060662	NA	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	colon: 1.1;endometrium: 1.3;testis: 2.8	small intestine: 0.6	Cell line enhanced	NA	AN3-CA: 1.0;LHCN-M2: 1.1;U-698: 1.2	Colon
DHRS9	3alpha-HSD, RDH15, RDHL, RETSDR8, SDR9C4	ENSG00000073737	Dehydrogenase/reductase 9	2	169064789-169096167	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036491, HPA036667	Approved	NA	NA	NA	Pancreatic cancer:2.73e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	colon: 66.5;rectum: 48.1	esophagus: 30.1	Cell line enhanced	NA	NB-4: 21.6;THP-1: 66.4;TIME: 35.4;U-2197: 29.3	Colon
ENTPD8	NTPDase-8, UNQ2492	ENSG00000188833	Ectonucleoside triphosphate diphosphohydrolase 8	9	137434364-137441816	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021509	Enhanced	NA	Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Stomach cancer:7.17e-4 (favourable)	Mixed	Tissue enhanced	NA	colon: 21.7;duodenum: 28.7;small intestine: 31.6	rectum: 12.5	Cell line enhanced	NA	CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7	Colon
FAM3D	EF7, OIT1	ENSG00000198643	Family with sequence similarity 3 member D	3	58633946-58666848	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013844	Approved	NA	NA	NA	Head and neck cancer:1.89e-4 (favourable), Breast cancer:7.51e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	colon: 318.5;rectum: 484.7	salivary gland: 191.6	Not detected	NA	NA	Colon
FCGBP	FC(GAMMA)BP	ENSG00000275395	Fc fragment of IgG binding protein	19	39863323-39934626	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003517, HPA003564	Enhanced	NA	Approved	Golgi apparatus<br>Plasma membrane<br>Cytokinetic bridge	Ovarian cancer:9.70e-6 (unfavourable), Head and neck cancer:1.28e-5 (favourable), Liver cancer:4.74e-5 (unfavourable), Thyroid cancer:4.27e-4 (unfavourable)	Expressed in all	Tissue enhanced	NA	colon: 166.7	cervix, uterine: 83.5	Cell line enhanced	NA	A549: 2.7;RH-30: 6.8	Colon
FFAR4	GPR120, GPR129, O3FAR1, PGR4	ENSG00000186188	Free fatty acid receptor 4	10	93566665-93604480	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042563	Uncertain	NA	Uncertain	Plasma membrane	NA	Tissue enhanced	Tissue enhanced	NA	colon: 8.4;rectum: 12.4	lung: 5.4	Cell line enhanced	NA	A549: 1.2;HaCaT: 2.0;NB-4: 1.6	Colon
FOXD2	FKHL17, FREAC9	ENSG00000186564	Forkhead box D2	1	47436017-47440691	Predicted intracellular proteins, Transcription factors	Evidence at protein level	NA	NA	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	colon: 3.4;rectum: 2.7	prostate: 1.1	Cell line enhanced	NA	AN3-CA: 11.3;WM-115: 17.4	Colon
FRMD1	bA164L23.1, DKFZp434O0117, FLJ00181, FLJ22615, FLJ40260	ENSG00000153303	FERM domain containing 1	6	168055745-168081557	Predicted intracellular proteins	Evidence at protein level	HPA030347	Supported	NA	Approved	Actin filaments	NA	Tissue enriched	Tissue enhanced	NA	colon: 5.8;stomach: 6.4;testis: 5.9	rectum: 4.6	Cell line enhanced	NA	K-562: 2.8	Colon
FUT3	CD174, LE	ENSG00000171124	Fucosyltransferase 3 (Lewis blood group)	19	5842888-5851474	Blood group antigen proteins, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046966	Supported	NA	NA	NA	Renal cancer:8.22e-7 (favourable), Breast cancer:6.86e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	colon: 68.0;esophagus: 83.0;small intestine: 63.1	rectum: 49.4	Group enriched	5	A-431: 40.5;RH-30: 14.4	Colon
FXYD3	MAT-8, PLML	ENSG00000089356	FXYD domain containing ion transport regulator 3	19	35115879-35124324	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010856	Enhanced	NA	NA	NA	Renal cancer:1.15e-6 (unfavourable)	Expressed in all	Tissue enhanced	NA	colon: 1455.6;rectum: 1952.1	stomach: 557.3	Cell line enhanced	NA	HaCaT: 792.6;hTCEpi: 1156.1;RT4: 686.4;SK-BR-3: 621.3;WM-115: 590.3	Colon
GCNT3	C2/4GnT, C2GnT-M, C2GnT2	ENSG00000140297	Glucosaminyl (N-acetyl) transferase 3, mucin type	15	59594875-59640239	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011154	Enhanced	NA	Approved	Golgi apparatus<br>Vesicles	Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	colon: 142.2;gallbladder: 118.0;rectum: 134.6;small intestine: 138.4	duodenum: 97.7	Cell line enriched	6	A549: 133.3	Colon
GPR15	NA	ENSG00000154165	G protein-coupled receptor 15	3	98531899-98533150	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA013775	Approved	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	colon: 25.0;rectum: 46.8	urinary bladder: 18.4	Group enriched	22	HDLM-2: 5.6;U-266/70: 1.9	Colon
GUCA2B	NA	ENSG00000044012	Guanylate cyclase activator 2B	1	42153421-42155824	Plasma proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 87.6;small intestine: 148.3	duodenum: 37.5	Group enriched	6	A549: 1.3;CACO-2: 3.2	Colon
HEPACAM2	FLJ38683	ENSG00000188175	HEPACAM family member 2	7	93188586-93226524	Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	Colorectal cancer:9.73e-5 (favourable)	Mixed	Tissue enhanced	NA	colon: 64.3;rectum: 103.1;small intestine: 53.6	duodenum: 30.2	Cell line enriched	47	SCLC-21H: 202.2	Colon
HOXD12	HOX4H	ENSG00000170178	Homeobox D12	2	176099730-176101193	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059444	Uncertain	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	colon: 1.0;rectum: 1.1;seminal vesicle: 1.8	prostate: 0.8	Cell line enhanced	NA	REH: 2.3	Colon
HSD11B2	SDR9C3	ENSG00000176387	Hydroxysteroid 11-beta dehydrogenase 2	16	67430652-67437553	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB032443, HPA042186, HPA056385	Enhanced	NA	Approved	Vesicles	Renal cancer:9.51e-5 (favourable)	Expressed in all	Tissue enhanced	NA	colon: 151.6;kidney: 173.3	salivary gland: 122.5	Cell line enhanced	NA	NTERA-2: 11.4;RPMI-8226: 9.6;RT4: 11.0;SCLC-21H: 17.5;SK-BR-3: 10.0	Colon
ITLN1	FLJ20022, hIntL, HL-1, ITLN, LFR	ENSG00000179914	Intelectin 1	1	160876539-160885170	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB012652, HPA063275, HPA067326	Enhanced	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 447.7;rectum: 1428.1;small intestine: 468.9	duodenum: 276.3	Cell line enhanced	NA	HEL: 2.3;HL-60: 1.5;U-937: 5.7	Colon
KLK15	ACO, HSRNASPH, prostinogen	ENSG00000174562	Kallikrein related peptidase 15	19	50825289-50837213	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019802	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 3.2;salivary gland: 2.4	adrenal gland: 1.8	Cell line enriched	5	RPMI-8226: 1.7	Colon
KRT20	CK20, K20, MGC35423	ENSG00000171431	Keratin 20	17	40875941-40885227	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000032, HPA024309, HPA024684, HPA027236	Enhanced	NA	Supported	Cytosol	Renal cancer:1.32e-4 (unfavourable), Liver cancer:7.05e-4 (unfavourable)	Group enriched	Tissue enhanced	NA	colon: 356.1;duodenum: 252.4;rectum: 295.3;small intestine: 499.6	stomach: 82.3	Cell line enhanced	NA	BEWO: 1.0;RT4: 2.3	Colon
LEFTY1	LEFTB, LEFTYB	ENSG00000243709	Left-right determination factor 1	1	225886282-225911382	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA047883, HPA056210	Approved	NA	NA	NA	Renal cancer:2.48e-6 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	colon: 58.4;pancreas: 20.4;rectum: 35.2	appendix: 9.6	Cell line enriched	7	NTERA-2: 50.6	Colon
LGALS4	GAL4	ENSG00000171747	Galectin 4	19	38801671-38813364	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025653, HPA031184, HPA031185, HPA031186	Enhanced	NA	Uncertain	Plasma membrane	Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)	Group enriched	Tissue enhanced	NA	colon: 736.0;duodenum: 526.9;rectum: 640.3;small intestine: 493.5	gallbladder: 138.8	Cell line enhanced	NA	CACO-2: 1.0;RT4: 2.2;SH-SY5Y: 1.0	Colon
LINC00675	NA	ENSG00000263429	Long intergenic non-protein coding RNA 675	17	10794913-10804099	Predicted membrane proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 36.9;rectum: 40.8;stomach: 44.3	duodenum,small intestine: 18.3	Cell line enriched	8	RT4: 3.2	Colon
MAB21L2	NA	ENSG00000181541	Mab-21 like 2	4	150581922-150584693	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049324, HPA059864	NA	NA	Enhanced	Nucleus<br>Cytosol	NA	Tissue enhanced	Tissue enhanced	NA	colon: 18.3;smooth muscle: 26.2	small intestine: 12.4	Group enriched	20	HHSteC: 4.9;SH-SY5Y: 16.0	Colon
MUC4	NA	ENSG00000145113	Mucin 4, cell surface associated	3	195746765-195812277	Predicted membrane proteins	Evidence at protein level	HPA005895, CAB013536	Approved	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 1.0	esophagus: 0.4	Not detected	NA	NA	Colon
NOXO1	P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28	ENSG00000196408	NADPH oxidase organizer 1	16	1978917-1984192	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071540	Enhanced	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	appendix: 6.3;colon: 7.4;rectum: 6.5	duodenum: 3.3	Cell line enhanced	NA	CAPAN-2: 2.4;HaCaT: 1.4;SCLC-21H: 1.6	Colon
NPY4R	PP1, PPYR1, Y4	ENSG00000204174	Neuropeptide Y receptor Y4	10	46461099-46465881	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA027863	Approved	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 5.1;rectum: 6.9	skin: 3.6	Cell line enriched	5	A549: 26.3	Colon
NRARP	MGC61598	ENSG00000198435	NOTCH-regulated ankyrin repeat protein	9	137300482-137302251	Predicted intracellular proteins	Evidence at transcript level	HPA025729	Approved	NA	Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.73e-6 (unfavourable)	Expressed in all	Tissue enhanced	NA	colon: 38.4	rectum: 22.0	Cell line enhanced	NA	HaCaT: 34.8;NTERA-2: 28.5;TIME: 23.6	Colon
NXPE2	FAM55B, FLJ25224	ENSG00000204361	Neurexophilin and PC-esterase domain family member 2	11	114678386-114706933	Predicted intracellular proteins	Evidence at protein level	HPA039744, HPA039876	Enhanced	NA	NA	NA	Colorectal cancer:9.29e-5 (favourable)	Tissue enhanced	Tissue enhanced	NA	colon: 9.5;epididymis: 30.3;rectum: 9.7	salivary gland: 8.2	Not detected	NA	NA	Colon
OTOP2	NA	ENSG00000183034	Otopetrin 2	17	74924275-74933912	Predicted membrane proteins	Evidence at transcript level	HPA024524, HPA053090	Uncertain	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	colon: 20.0;rectum: 11.4	testis: 3.9	Cell line enriched	50	HDLM-2: 9.6	Colon
PADI2	KIAA0994, PDI2	ENSG00000117115	Peptidyl arginine deiminase 2	1	17066761-17119435	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047735	Enhanced	NA	NA	NA	NA	Mixed	Tissue enhanced	NA	cerebral cortex: 85.0;colon: 89.8;rectum: 99.9;skeletal muscle: 108.6	breast: 48.8	Group enriched	5	A549: 10.4;RPTEC TERT1: 25.1;SK-BR-3: 38.1;T-47d: 13.1	Colon
PIGR	NA	ENSG00000162896	Polymeric immunoglobulin receptor	1	206928518-206946466	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006154, CAB009454, HPA012012	Enhanced	NA	NA	NA	Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable)	Tissue enhanced	Tissue enhanced	NA	colon: 1688.0;duodenum: 2659.3	rectum: 1335.9	Cell line enriched	7	EFO-21: 33.8	Colon
PIGZ	FLJ12768, MGC52163, SMP3	ENSG00000119227	Phosphatidylinositol glycan anchor biosynthesis class Z	3	196946343-196969060	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA058599, HPA059920	Approved	NA	Uncertain	Vesicles	Renal cancer:5.60e-5 (unfavourable)	Expressed in all	Tissue enhanced	NA	colon: 18.5;rectum: 18.1	cerebral cortex: 10.9	Mixed	NA	NA	Colon
PKIB	PRKACN2	ENSG00000135549	CAMP-dependent protein kinase inhibitor beta	6	122471917-122726373	Predicted intracellular proteins	Evidence at protein level	HPA030156	Approved	NA	NA	NA	Renal cancer:2.47e-7 (favourable), Liver cancer:4.72e-7 (unfavourable)	Expressed in all	Tissue enhanced	NA	colon: 89.1;placenta: 85.4	parathyroid gland: 78.0	Cell line enhanced	NA	AF22: 71.0;PC-3: 106.9;RPTEC TERT1: 141.0;SCLC-21H: 186.3	Colon
PLA2G10	GXPLA2	ENSG00000069764	Phospholipase A2 group X	16	14672545-14694669	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA041893	Uncertain	NA	NA	NA	Endometrial cancer:5.74e-5 (favourable)	Mixed	Tissue enhanced	NA	colon: 6.9;rectum: 6.5;stomach: 10.4	duodenum: 2.2	Cell line enhanced	NA	CAPAN-2: 1.3	Colon
PLA2G2A	PLA2B, PLA2L	ENSG00000188257	Phospholipase A2 group IIA	1	19975431-19980416	Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA015236	Enhanced	NA	Uncertain	Nucleus<br>Nucleoli	Melanoma:1.49e-4 (favourable)	Expressed in all	Tissue enhanced	NA	colon: 108.4;rectum: 177.5;small intestine: 233.7	duodenum: 85.7	Group enriched	11	Hep G2: 50.2;RT4: 53.3	Colon
REP15	RAB15EP	ENSG00000174236	RAB15 effector protein	12	27696519-27697596	Predicted intracellular proteins	Evidence at protein level	HPA040448, HPA059868	Approved	NA	NA	NA	Colorectal cancer:9.43e-5 (favourable)	Mixed	Tissue enhanced	NA	colon: 39.7;rectum: 70.4;stomach: 82.2	small intestine: 39.4	Mixed	NA	NA	Colon
RETNLB	FIZZ2, HXCP2, RELMb	ENSG00000163515	Resistin like beta	3	108743424-108757384	Predicted secreted proteins	Evidence at transcript level	HPA049152	Approved	NA	NA	NA	Colorectal cancer:6.86e-5 (favourable)	Tissue enriched	Tissue enhanced	NA	colon: 73.5;rectum: 270.7	small intestine: 36.9	Not detected	NA	NA	Colon
RP11-599B13.6	NA	ENSG00000263620	NA	17	8150816-8162975	Predicted membrane proteins	Evidence at transcript level	NA	NA	NA	NA	NA	NA	Not detected	Tissue enhanced	NA	colon: 5.2;spleen: 5.1;stomach: 4.5	adipose tissue: 3.8	Cell line enhanced	NA	HDLM-2: 28.8;HEK93: 11.5;REH: 14.0	Colon
RXFP4	GPCR142, GPR100, RLN3R2, RXFPR4	ENSG00000173080	Relaxin/insulin like family peptide receptor 4	1	155941710-155942949	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 2.0;duodenum: 1.4;rectum: 2.2	small intestine: 1.1	Not detected	NA	NA	Colon
SLC22A18AS	BWR1B, BWSCR1B, ORCTL2S, p27-BWR1B, SLC22A1LS	ENSG00000254827	Solute carrier family 22 member 18 antisense	11	2887780-2903740	Predicted intracellular proteins	Evidence at protein level	HPA068288	Enhanced	NA	Supported	Nucleoplasm	NA	Mixed	Tissue enhanced	NA	colon: 14.4;duodenum: 13.5	small intestine: 11.0	Cell line enhanced	NA	A549: 8.7;CAPAN-2: 8.3;MCF7: 14.0;SK-MEL-30: 26.1;WM-115: 14.7	Colon
SLC26A2	DTD, DTDST	ENSG00000155850	Solute carrier family 26 member 2	5	149960737-149993455	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041957, HPA058090	Enhanced	NA	Approved	Vesicles	Renal cancer:3.27e-4 (unfavourable), Liver cancer:4.66e-4 (unfavourable), Endometrial cancer:7.29e-4 (favourable)	Expressed in all	Tissue enhanced	NA	colon: 213.0;rectum: 207.1	parathyroid gland: 82.7	Expressed in all	NA	NA	Colon
SLC26A3	CLD, DRA	ENSG00000091138	Solute carrier family 26 member 3	7	107765467-107803225	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036055	Approved	NA	NA	NA	NA	Tissue enriched	Tissue enhanced	NA	colon: 1075.0;duodenum: 577.9;rectum: 961.7	seminal vesicle: 185.8	Cell line enhanced	NA	RPMI-8226: 1.9	Colon
SLC9A2	NHE2	ENSG00000115616	Solute carrier family 9 member A2	2	102619707-102711318	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035121, HPA035122	Approved	NA	Supported	Cell Junctions	NA	Mixed	Tissue enhanced	NA	colon: 20.5;rectum: 23.3;stomach: 25.7	testis: 10.7	Cell line enhanced	NA	A-431: 8.9;RT4: 13.9;SK-BR-3: 11.4;T-47d: 18.0	Colon
SLC9A3	NHE3	ENSG00000066230	Solute carrier family 9 member A3	5	473310-524332	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036493, HPA036669	Enhanced	NA	Supported	Plasma membrane	Melanoma:8.49e-4 (unfavourable)	Mixed	Tissue enhanced	NA	colon: 80.9;gallbladder: 66.1;small intestine: 72.6	kidney: 57.3	Cell line enhanced	NA	HDLM-2: 30.4	Colon
ST6GALNAC1	SIAT7A, ST6GalNAcI	ENSG00000070526	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1	17	76624761-76643838	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014975	Uncertain	NA	NA	NA	Head and neck cancer:2.54e-5 (favourable)	Mixed	Tissue enhanced	NA	colon: 162.6;rectum: 235.5	cervix, uterine: 90.7	Cell line enhanced	NA	EFO-21: 9.1;HaCaT: 9.7;HEL: 16.1;K-562: 48.8	Colon
TFF3	HITF, ITF	ENSG00000160180	Trefoil factor 3	21	42311667-42315651	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB020681, HPA035464	Enhanced	NA	Approved	Nucleus<br>Nucleoli	Endometrial cancer:5.60e-6 (favourable)	Expressed in all	Tissue enhanced	NA	cervix, uterine: 470.7;colon: 496.2;rectum: 504.3;thyroid gland: 620.1	small intestine: 457.0	Cell line enhanced	NA	MCF7: 63.2;SCLC-21H: 28.3;T-47d: 35.0;TIME: 85.5	Colon
TMEM171	PRP2	ENSG00000157111	Transmembrane protein 171	5	73120292-73131817	Predicted membrane proteins	Evidence at protein level	HPA042308	Approved	NA	NA	NA	Renal cancer:3.93e-10 (favourable)	Mixed	Tissue enhanced	NA	colon: 32.4;rectum: 32.3;thyroid gland: 47.1	duodenum: 26.3	Cell line enhanced	NA	LHCN-M2: 48.9;WM-115: 161.7	Colon
TPSG1	PRSS31, TMT	ENSG00000116176	Tryptase gamma 1	16	1221651-1225257	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA060458	Enhanced	NA	NA	NA	Renal cancer:1.76e-8 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	colon: 14.6;duodenum: 14.3;rectum: 9.5;small intestine: 10.5	ovary: 2.5	Group enriched	8	HMC-1: 20.4;MCF7: 6.0	Colon
TRABD2A	C2orf89, TIKI1	ENSG00000186854	TraB domain containing 2A	2	84821650-84907008	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045817	Approved	NA	NA	NA	NA	Group enriched	Tissue enhanced	NA	colon: 35.4;ovary: 30.7;rectum: 43.1	lymph node: 11.7	Cell line enhanced	NA	BEWO: 38.1;HDLM-2: 29.0;hTEC/SVTERT24-B: 17.5;SiHa: 18.3	Colon
TRIM15	RNF93, ZNF178, ZNFB7	ENSG00000204610	Tripartite motif containing 15	6	30163206-30172696	Predicted intracellular proteins	Evidence at protein level	HPA047527	Uncertain	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 2.6;duodenum: 3.6	appendix,small intestine: 1.1	Cell line enriched	24	HEL: 15.2	Colon
TRPM6	CHAK2, FLJ22628, HOMG, HSH	ENSG00000119121	Transient receptor potential cation channel subfamily M member 6	9	74722495-74888094	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 13.1;rectum: 18.2	small intestine: 8.7	Cell line enhanced	NA	BEWO: 3.7;HeLa: 1.5;RT4: 3.0	Colon
TSPAN1	NET-1, TSPAN-1	ENSG00000117472	Tetraspanin 1	1	46175073-46185958	Predicted membrane proteins	Evidence at protein level	HPA011909	Approved	NA	Approved	Nucleoplasm<br>Vesicles	Renal cancer:9.28e-6 (favourable)	Expressed in all	Tissue enhanced	NA	colon: 525.0;rectum: 651.6	prostate: 311.2	Cell line enhanced	NA	CAPAN-2: 191.2;HaCaT: 134.4;hTCEpi: 125.3;RPTEC TERT1: 474.4;RT4: 246.2	Colon
TSPAN8	CO-029, TM4SF3	ENSG00000127324	Tetraspanin 8	12	71125085-71441898	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	CAB026009, HPA044337	Enhanced	NA	Approved	Nucleoplasm	Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	colon: 910.6;duodenum: 905.9;rectum: 911.5;small intestine: 909.2	stomach: 573.4	Cell line enhanced	NA	CACO-2: 36.0;HeLa: 34.8;PC-3: 151.7;RT4: 30.6	Colon
UGT1A10	UGT1J	ENSG00000242515	UDP glucuronosyltransferase family 1 member A10	2	233636454-233773305	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	NA	NA	NA	NA	NA	Pancreatic cancer:4.55e-4 (unfavourable)	Tissue enhanced	Tissue enhanced	NA	colon: 49.7;duodenum: 80.9;small intestine: 59.1	rectum: 39.6	Cell line enriched	108	RT4: 416.9	Colon
UGT1A8	UGT1H	ENSG00000242366	UDP glucuronosyltransferase family 1 member A8	2	233617645-233773310	Enzymes, Predicted membrane proteins	Evidence at protein level	NA	NA	NA	NA	NA	NA	Tissue enhanced	Tissue enhanced	NA	colon: 16.0;gallbladder: 10.3;rectum: 9.7;urinary bladder: 22.7	small intestine: 4.9	Cell line enriched	53	RT4: 96.7	Colon
UGT2B17	NA	ENSG00000197888	UDP glucuronosyltransferase family 2 member B17	4	68537184-68568527	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Supported	NA	NA	NA	NA	Group enriched	Tissue enhanced	NA	colon: 372.4;duodenum: 371.2;small intestine: 522.5	rectum: 151.7	Cell line enhanced	NA	RPMI-8226: 1.2	Colon
